~~Timely~~timely delivery of a valid, later-dated proxy; or

~~Voting in person~~

entering a new vote online before the cutoff time (11:59 p.m., EST, on August 23, 2021); or

attending and voting online during the Annual Meeting (although attendance at the Annual ~~Meeting.~~Meeting will not, by itself, revoke a proxy).

Your latest proxy submitted before the Annual Meeting is the one that will be counted, unless you are admitted to attend the Annual Meeting and vote your shares online during the meeting.

Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Nominee

If you are athe beneficial owner of your shares, ~~held in street name,~~ you ~~should follow~~must contact the ~~instructions of your~~broker, bank ~~broker~~ or other nominee holding your shares and follow their instructions to change your vote or revoke your ~~voting instructions.~~proxy. You may also vote ~~in person at~~online during the Annual Meeting if you ~~obtain~~have obtained a legal proxy as described above.

~~Can I attend the Annual Meeting?~~

You are invited to attend the Annual Meeting if you are a registered stockholder or a beneficial owner as of the record date or if you hold a valid proxy for the Annual Meeting. To enter the Annual Meeting, you must be prepared to present photo identification acceptable to us, such as a valid driver’s license or passport. In addition, if you are a beneficial owner, you will need to provide proof of beneficial ownership on the record date, such as an account statement showing your ownership on the record date, a copy of the voting instruction card provided by your broker, trustee or nominee, or other similar evidence of ownership.

What constitutes a quorum at the Annual Meeting?

The presence, ~~in person~~by attendance at the Annual Meeting or by proxy, of the holders of a majority in voting power of the shares of our Common Stock issued and outstanding and entitled to vote at the Annual Meeting must be present or represented to conduct business at the Annual Meeting. You will be considered part of the quorum if you ~~return a signed and dated~~are represented by proxy ~~card~~ or if you attend the virtual Annual Meeting.

Abstentions and withhold votes are counted as “shares present” at the Annual Meeting for purposes of determining whether a quorum exists. Proxies submitted by banks, brokers or other holders of record holding shares for you as a beneficial owner that do not indicate a vote for some or all of the proposals because that holder does not have voting authority and has not received voting instructions from you(so-called “brokernon-votes”) are also considered “shares present” for purposes of determining whether a quorum exists. If you are a beneficial owner, these holders are permitted to vote your shares on the ratification of the appointment of our independent registered public accounting firm, even if they do not receive voting instructions from you.

What is the voting requirement to approve each of the proposals?

The following table summarizes the vote threshold required for approval of each item of business to be transacted at the Annual Meeting, provided that there is a quorum. In addition, the table shows the effect on the outcome of the vote of: (i) abstentions (or, in the case of Proposal 1, withhold votes); (ii) uninstructed shares held by brokers (which result in brokernon-votes when a beneficial owner of shares held in “street name” does not provide voting instructions and, as a result, the nominee is prohibited from voting those shares on certain proposals); and (iii) signed but unmarked proxy cards.


Proposal	Vote Required for Approval	Effect of Abstentions/ Withhold Votes (1)	Uninstructed Shares/ Effect of Broker Non-Votes (1)	Signed but Unmarked Proxy Cards (2)
1. Election of Directors	Plurality of Votes Cast	No effect	Not voted / no effect	Voted “For” each nominee

~~2. Ratification of appointment of independent registered public accounting firm~~	~~Majority of shares present in person or represented by proxy and entitled to~~ ~~vote~~	~~Same effect~~ ~~as a vote~~ ~~“Against”~~	~~Discretionary vote by broker~~	~~Voted “For”~~


3.Proposal	Vote Required for Approval	Effect of Abstentions/ Withhold Votes (1)	Uninstructed Shares/ Effect of Broker Non-Votes (1)	Signed but Unmarked Proxy Cards (2)
2. Approval of ~~the~~ Amended and Restated 2016 Stock Option Plan forNon-Employee Directors	Majority of shares present ~~in person~~ at the Annual Meeting or represented by proxy and entitled to vote thereon	Same effect as a vote ~~“Against”~~ “Against”	Not voted / no effect	Voted “For”

~~4. Advisory Vote On Executive Compensation~~3. Ratification of appointment of independent registered public accounting firm	Majority of shares present ~~in person~~at the Annual Meeting or represented by proxy and entitled to vote thereon	Same effect as a vote ~~“Against”~~ “Against”	~~Not voted / no effect~~Discretionary vote by broker	Voted “For”

(1)
~~5. Advisory Vote On Frequency Of Future Advisory Votes On Executive Compensation~~		~~Frequency (every year, every two years or every three years) that receives the most votes cast by the shares~~Abstentions and broker non-votes are included for purposes of determining whether a quorum is present, ~~in person or represented by proxy and entitled~~however, abstentions are considered “entitled to ~~vote~~		~~No effect~~		~~Not voted / no effect~~		~~Voted for “Two Years”~~vote” whereas broker non-votes are not.

(2)

~~(1) Abstentions and brokernon-votes~~ ~~are included for purposes of determining whether a quorum is present, however, abstentions are considered “entitled to vote” whereas brokernon-votes~~ ~~are not.~~

~~(2)~~ If you sign and return your proxy card properly, but do not provide instructions on your proxy card as to how to vote your shares, your shares will be voted as shown in this column and in accordance with the judgment of the individuals named as proxies on the proxy card as to any other matter properly brought before the Annual Meeting.

Under the rules of the NASDAQ Stock Market (“Nasdaq”), without voting instructions from beneficial owners, brokers will have discretion to vote on the ratification of the appointment of the independent registered public accounting firm but not on the other proposals. Therefore, for your voice to be heard, it is important that you vote.

As of the record date, Steve Hoffman, our Chief Executive Officer, Chief Science Officer and Chairman, beneficially owned 26.3% and Michael Demurjian, our Chief Operating Officer and a director, beneficially owned 26.3% of our issued and outstanding Common Stock. Messrs. Hoffman and Demurjian are also each candidates for~~re-election~~ as a Class I director at the Annual Meeting. They have agreed to vote together on matters submitted to a stockholder vote and have informed us that they intend to vote “For” the three proposals. As a result of their collective ownership interest of 52.6% of our issued and outstanding Common Stock as of the record date, they have the ability to decide all matters to be voted upon at the Annual Meeting.

~~What are the implications of having recently ceased being an “emerging growth company”?~~

~~We previously were, but beginning on March 31, 2018 we ceased to be, an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Our loss of emerging growth company status triggers the requirement to hold advisory votes on compensation and to comply with the pay ratio disclosure requirements of Item 402(u) of RegulationS-K.~~ Due to applicable transition relief, however, we are not required to provide pay ratio disclosure in this Proxy Statement. We expect to include pay ratio disclosure for the first time in the proxy statement we file in 2019.

Who pays for the cost of this proxy solicitation?

We will pay all the costs of preparing, mailing and soliciting the proxies. We will ask brokers, banks, voting trustees and other nominees and fiduciaries to forward ~~the proxy materials~~any Proxy Materials to the beneficial owners of our Common Stock and to obtain the authority to execute proxies. We will reimburse them for their reasonable expenses upon request. In addition to mailing proxy materials, our directors, officers and employees may solicit proxies in person, by telephone or otherwise. These individuals will not be specially compensated.

Where can I find the voting results of the Annual Meeting?

We will announce preliminary voting results at the Annual Meeting. We also will disclose voting results on a Current Report on Form8-K that we will file with the ~~Securities and Exchange Commission (“~~SEC~~”),~~ within four business days after the Annual Meeting.

How do I submit a stockholder proposal for consideration at next year’s annual meeting of stockholders?

For a proposal to be included in our proxy statement for the ~~2019~~2022 annual meeting of stockholders, you must submit it no later than March ~~28, 2019~~.14, 2022. Your proposal must be in writing and comply with the proxy rules of the SEC. ~~You should send~~Send your proposal to: Tyme Technologies, Inc., ~~17 State Street – 7th Floor, New York, NY 10004,~~1 Pluckemin Way, Suite 103, Bedminster, NJ 07921, Attention: Corporate Secretary.

You also may submit a proposal that you do not want included in the proxy statement but that you want to raise at the ~~2019~~2022 annual meeting of stockholders. We must receive this type of proposal in writing on or after April ~~25, 2019,~~26, 2022, but no later than May ~~25, 2019.~~26, 2022.

As detailed in our Amended and RestatedBy-laws (our “By-Laws”), to bring a proposal other than the nomination of a director before an annual meeting of stockholders, your notice of proposal must include: (i) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (ii) the text of the proposal or business (including the exact text of any

resolutions proposed for consideration and, in the event that such business includes a proposal to amend theBy-Laws, the exact text of the proposed amendment), (iii) a description of any material interest of such stockholder or such beneficial owner and the respective affiliates and associates of, or others acting in concert with, such stockholder or such beneficial owner in such business, (iv) any other information relating to such stockholder and such beneficial owner, that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for the proposal and pursuant to and in accordance with Regulation 14A of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and (v) the other information described in Article II, Section 9(b) of ourBy-Laws.

How do I nominate or recommend a director nominee?

If you wish to nominate an individual for election as director at the ~~2019~~2022 annual meeting of stockholders, we must receive your written nomination on or after April ~~25, 2019,~~26, 2022, but no later than May ~~25, 2019. You should send~~26, 2022. Send your nomination proposal to: Tyme Technologies, Inc., ~~17 State Street – 7th Floor, New York, NY 10004,~~1 Pluckemin Way, Suite 103, Bedminster, NJ 07921, Attention: Corporate Secretary.

As detailed in ourBy-Laws, for a nomination to be properly brought before an annual meeting, your notice of nomination must include: (i) the name, age, business address and, if known, residence address of each proposed nominee, (ii) the principal occupation or employment of each such nominee, (iii) the class and number of shares of Tyme Common Stock that are, directly or indirectly, owned, beneficially or of record, ~~and beneficially~~ by each nominee, (iv) a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships between or among (x) the stockholder, the beneficial owner, if any, on whose behalf the nomination is being made and the respective affiliates of, or others acting in concert with, such stockholder and such beneficial owner, on the one hand, and (y) each proposed nominee, and his or her respective affiliates and associates, or others acting in concert with such nominee(s) on the other hand, including all information that would be required to be disclosed pursuant to Item 404 of RegulationS-K if the stockholder making the nomination and any beneficial owner on whose behalf the nomination is made or any affiliate or associate thereof or person acting in concert therewith were the registrant for purposes of such Item 404 and the proposed nominee were a director or executive officer of such registrant, (v) such other information concerning each nominee that is

required to be disclosed in solicitations for proxies for election of directors pursuant to Regulation 14A under the Exchange Act or applicable law, (vi) the written consent of the nominee to serve as a director if elected, and (vii) the other information as specified in Article II, Section 10(b) of ourBy-Laws, including in regards of the proposing stockholder and the beneficial owner, if any, on whose behalf the nomination is made.

In addition to a stockholder’s ability to nominate candidates to serve on the Board, stockholders may recommend candidates to the Nominating and Corporate Governance Committee for consideration. The committee will consider recommendations from stockholders regarding director nominee candidates that are received in writing and accompanied by sufficient information to enable the committee to assess the candidate’s qualifications, along with confirmation of the candidate’s consent to serve as a director if elected. Such recommendations should be sent to our Corporate Secretary at our headquarters. Any recommendation received from a stockholder after March 31 of any year is not assured of being considered for nomination in that year.

PROPOSAL NO. 1

ELECTION OF DIRECTORS

Our Amended and Restated Certificate of Incorporation, as amended (our “Certificate of Incorporation”), andBy-Laws provide that the number of directors to hold office at any time may be determined from time to time by resolution of our Board. Our Board has set the size of the Board at ~~nine~~eight members. ~~Our~~

As discussed below under “Corporate Governance—Leadership and Board Structure,” our Board is divided into three classes, designated as Class I, Class II and Class III. Upon the expiration of the initial term of office for each class of directors, each director in that class will be elected for a three-year term and serve until ahis or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. Because of our classified board structure, we are only nominating our incumbent Class I directors, whose terms expire this year, for reelection at the 2021 Annual Meeting.

The table below sets forth information with respect to our directors as of ~~June 25, 2018:~~July 1, 2021:

Name

Age

Date Elected to our
Board of Directors

Class I Directors - Term Expiring at the ~~2018~~2021 Annual Meeting

Donald W. DeGolyer

May 24, 2018

Steve Hoffman

5558

March 5, 2015

~~Michael Demurjian~~

~~March 5, 2015~~

~~Donald W. DeGolyer~~

~~May 24, 2018~~

Class II Directors - Term Expiring at the ~~2019~~2022 Annual Meeting

Richard Cunningham

November 30, 2020

Gerald H. Sokol

7578

March 10, 2015

~~Tommy G. Thompson~~

~~February 5, 2018~~

Timothy C. Tyson

6669

March 10, 2015

Class III Directors - Term Expiring at the ~~2020~~2023 Annual Meeting

~~James Biehl~~David Carberry

5468

March 30, 2017

~~David Carberry~~Douglas A. Michels

6564

~~March 30, 2017~~October 1, 2018

Paul L. Sturman

5760

March 2, 2017

~~Messrs.~~

Mr. Hoffman ~~and Demurjian~~ served as ~~the sole directors~~a director of Tyme, Inc. ~~(or Tyme, our~~(our subsidiary) since its formation on July 26, 2013 and ~~have~~has served as ~~directors~~director of the Company since the completion of the merger on March 5, 2015 among us, our wholly-owned subsidiary formed for the purposes of completing the merger, Tyme, Inc. and certain other ~~parties (the “Merger”).~~

**	~~Mr. Thompson previously served as a special advisor to our Board and before that served as a member of our Board.~~parties.

The terms of our ~~three~~two Class I directors expire at the ~~2018~~2021 Annual Meeting. ~~After~~Upon the recommendation of our Nominating and Corporate Governance Committee and after consideration by the full Board, our Board has nominated Messrs. DeGolyer and Hoffman ~~Demurjian and DeGolyer~~ forre-election as Class I directors. Biographical information for each director and director nominee is contained below. If elected at the Annual Meeting, each of these nominees will serve for a three-year term expiring at the ~~2021~~2024 annual meeting of stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. Messrs. ~~Hoffman, Demurjian~~DeGolyer and ~~DeGolyer~~Hoffman have agreed to serve if elected, and we have no reason to believe that any of the nominees will be unable to serve. If a nominee is not able to serve, proxies will be voted in favor of the other nominees and may be voted for a substitute nominee, unless our Board chooses to reduce the number of directors serving on our Board. Unless otherwise instructed, the proxy holders will vote the proxies received by them “FOR” the election of Messrs. ~~Hoffman, Demurjian~~DeGolyer and ~~DeGolyer~~Hoffman as Class I directors.

The following is a brief biographical summary of the experience of our directors and director nominees:

Nominees for election at our ~~2018~~2021 Annual Meeting with terms expiring at the 2021 Annual Meeting.

Donald W. DeGolyer has been a member of our Board since May 2018. Mr. DeGolyer is the Founder and a director of Vertice Pharma, LLC, a specialty pharmaceuticals company focused on improving patients’ health,

and has served in ~~2021.~~that role since 2015. He is also a director and member of the compensation committee of HLS Therapeutics Inc. (TSXV: HLS), a specialty pharmaceutical company listed on the TSX Exchange in Canada. Mr. DeGolyer has over 30 years of experience in the pharmaceuticals industry. He was previously the Chief Operating Officer of Endo Pharmaceuticals from 2013 to 2015 where he built a high-growth specialty pharmaceuticals business. He also served as President and CEO of Sandoz North America from 2010 to 2013 as it became the one of the largest generics companies in the world. Mr. DeGolyer began his career at Pfizer, Johnson & Johnson and then Novartis, progressing through various roles of increasing responsibility.

Our Board believes that Mr. DeGolyer’s significant experience in the pharmaceuticals industry and experience in founding and growing businesses allow him to make valuable contributions to the Board.

Steve Hoffman ~~has been~~served as Chief Executive Officer of ~~our wholly-owned subsidiary, Tyme, Inc., since its formation in July 2013,~~the Company from March 2015 until November 2020, and ~~a manager of our wholly-owned subsidiary, Luminant Biosciences, LLC, since its formation in September 2011. In such roles and continuing with his current position~~he remains as ~~Chief Executive Officer and~~ Chief Science Officer, ~~of the Company, which commenced~~having served in that role since March ~~2015, he supervises~~2015. In his role, Mr. Hoffman continues to supervise the development of our product ~~candidates. He has~~candidates that he began with Tyme, Inc. and the wholly-owned subsidiary of the Company and the Company’s dissolved former subsidiary, Luminant Bioscience LLC (“Luminant”). Prior to the establishment of Luminant in 2011, he held a variety of senior management positions with companies in the chemistry, aerospace and laser optics fields for over 25 years. ~~Prior to the establishment of Luminant,~~ Mr. Hoffman was aco-founder and, from 1993 to 2007, Chief Technology Officer of Mikronite Technologies Group Inc., a developer, licensor and marketer of material surfacing technologies for various manufacturing processes and applications. At Mikronite, Mr. Hoffman supervised its implementation of proprietary technology. His efforts on behalf of Mikronite were recognized by The Home Depot and Lowe’s with a Best New Product award and an Innovative Technology award from the New Jersey Manufacturers Association. Mr. Hoffman attended New York University and Rutgers University with a concentration in mechanical engineering from 1980 to 1984 and continued his studies under the direct supervision of the chairman of the physics department at the University of Michigan specializing in physics and electro-optics.

Our Board believes that Mr. Hoffman’s detailed knowledge of our Company since its founding and extensive executive experience in technology and science prior to joining Tyme provide a unique critical contribution of skills to the Board.

~~Michael Demurjian~~ has been Chief Operating Officer of our wholly-owned subsidiary, Tyme, Inc., since its formation in July 2013, and a manager of our wholly-owned subsidiary Luminant Biosciences, LLC, since its formation in September 2011. In such roles and continuing with his position as Chief Operating Officer and Executive Vice President of our Company, which commenced in March 2015, he leads the teams in studies and data collection activities for our submissions to regulatory authorities, including the FDA. Prior to the establishment of Luminant, Mr. Demurjian was a~~co-founder~~ and, from 1993 to 2007, Director of Marketing of Mikronite Technologies Group, Inc., a developer, licensor and marketer of material surfacing technologies for various manufacturing processes and applications. At Mikronite, Mr. Demurjian established all marketing activities and functions, marketing research and analysis, marketing strategy, implementation planning, project, process and vendor management organizational management and leadership. His efforts on behalf of Mikronite were recognized by The Home Depot and Lowe’s with a Best New Product award and an Innovative Technology award from the New Jersey Manufacturers Association. Mr. Demurjian received a BA in Economics from New York University in 1986.

Our Board believes that Mr. Demurjian’s detailed knowledge of our Company since its founding and extensive executive experience in marketing, strategy and operations prior to joining Tyme provide a unique critical contribution of skills to the Board.

~~Donald W. DeGolyer~~ is the Founder, Chief Executive Officer, and a Director of Vertice Pharma, LLC, a specialty pharmaceuticals company focused on improving patients’ health, and has served in that role since 2015. He was previously the Chief Operating Officer of Endo Pharmaceuticals from 2013 to 2015. Before that, he served as President & CEO of Sandoz North America from 2010 to 2013. Mr. DeGolyer also held various leadership roles at Pfizer Inc., Johnson & Johnson and Novartis AG, in all totaling over 34 years of experience in the pharmaceuticals industry.

Directors continuing in office with terms expiring in ~~2019.~~2022.

Richard Cunningham joined as the Chief Executive Officer and a director of the Company in November 2020. He brings over 20 years of leadership experience in the healthcare and biopharmaceutical industry. Immediately before joining Tyme, Mr. Cunningham was the Chief Executive Officer and President of IXC Discovery, Inc. (formerly, Icagen Inc.), a drug discovery company, which positions he held beginning in November 2014. He had also served as a director there since April 2020. Before IXC Discovery, Inc., Mr. Cunningham held various roles at pharmaceutical and healthcare companies, including Boehringer Ingelheim and Valeant Pharmaceuticals (now, Bausch Health Companies Inc.; NYSE: BHC). His experience includes a broad array of responsibilities, including mergers and acquisitions, business development, strategy development, therapeutic launches, contracting, managed care, and sales and marketing. He has led the commercialization and launch of multiple therapies in oncology, rare disease, infectious disease, respiratory, neurology, cardiovascular and metabolic diseases.

Our Board believes that Mr. Cunningham’s leadership expertise, significant experience in mergers and acquisitions, business development and knowledge of the pharmaceutical industry enable him to make valuable contributions to our Board.

Gerald H. Sokol, MD, MSc, FCP has been a member of our Board since March 2015. He also serves on our Medical Advisory Board and as chairman of our Science Development Committee. Dr. Sokol attained his medical degree from Indiana University’s Combined Degree Program in Experimental Medicine together with a Master’s Degree in Pharmacology. He interned in medicine at Temple University and attended the U.S. Public

Health Service Hospital in affiliation with the National Cancer Institute, Johns Hopkins and the University of Maryland completing training in internal medicine. He then completed training at the Massachusetts General Hospital, Harvard Medical School in Radiation Oncology, Medical Oncology and Clinical Pharmacology, attaining Board Certifications in Internal Medicine, Medical Oncology, Radiation Oncology, Clinical Pharmacology, and later Quality Assurance and Utilization Review. He also is certified in Skin Cancer Medicine from the University of Queensland. Dr. Sokol has been Chief of Radiation Oncology at the University of South Florida’s Tampa General Hospital and has built or contributed to building over ten cancer centers. He is a board member and partner of Florida Cancer Specialists and Research Institute. Dr. Sokol is a decorated retired Captain in the US Navy and served as a Commanding Officer at the Uniformed Services University. Dr. Sokol currently holds professorships in Medicine and Pharmacology at that institution. While maintaining a medical practice, Dr. Sokol served on the review staff of the FDA for over 27 years as a senior regulatory scientist and officer, composing over 300 white papers, IND and NDA reviews and opinion papers. Dr. Sokol has authored or coauthored over 100 books, book ~~chapter,~~chapters, abstracts and papers on a multitude of clinical issues. He is a lifetime fellow and board member of the American Cancer Society and a fellow of the American College of Clinical Pharmacology.

Our Board believes that Dr. Sokol’s strategic insight and extensive experience in drug approval and development, and knowledge as a physician, allow him to make valuable contributions to the Board.

~~Thomas (“Tommy”) G. Thompson~~ currently is the Chairman and Chief Executive Officer of Thompson Holdings, and former United States Health and Human Services (HHS) Secretary and four-term Governor of Wisconsin. Governor Thompson, through his work at Thompson Holdings, continues to develop innovative solutions to the health care challenges facing American families, businesses, communities, states and the nation as a whole. These efforts focus on improving the use of information technology in hospitals, clinics and doctors’ offices; promoting healthier lifestyles; strengthening and modernizing Medicare and Medicaid; and expanding the use of medical diplomacy around the world. From 2005 until 2009, Governor Thompson served as a senior advisor at the consulting firm Deloitte LLP and was the founding independent chairman of the Deloitte Center for Health Solutions, which researches and develops solutions to some of our nation’s most pressing health care and public health related challenges. From 2005 to early 2012, Governor Thompson served as a senior partner at the law firm of Akin, Gump, Strauss, Hauer, & Feld LLP. Governor Thompson served as Chairman of the Board of Directors of Logistics Health, Inc. from January 2011 to May 2011, and served as President from February 2005 to January 2011. He currently serves on the Board of Directors of the following public companies: Physicians Realty Trust and TherapeuticsMD, Inc., each as Chairman of the Board of Directors, and Centene Corporation, and United Therapeutics Corporation. Mr. Thompson also previously served on the board of C.R. Bard, Inc. from 2005 to 2017 and Cytori Therapeutics, Inc. from 2011 to 2016.

Our Board believes that Mr. Thompson’s significant experience in the healthcare field, as well as his extensive experience in public service and as a director on public and private boards, allow him to make valuable contributions to the Board.

Timothy C. Tyson has been a member of our Board since March 2015. Mr. Tyson is currently Chairman and CEO of ~~Avara~~TriRx Pharmaceutical Services, LLC and Chairman at Icagen Inc. He served as Chairman and CEO of Avara Pharmaceutical Services from May 2015 to October 2018. He served as Chief Executive Officer and Executive Chairman of Aptuit from 2008 to 2012 andnon-executive Chairman from 2012 to 2016. Mr. Tyson served as the Chief Executive Officer of Valeant Pharmaceuticals International (formerly, ICN Pharmaceuticals Inc.) from January 1, 2005 to February 1, 2008. He served as President of Valeant Pharmaceuticals International from November 2002 to February 1, 2008 and served as its Chief Operating Officer from November 2002 to December 2004. He served as President of Global Manufacturing and Supply for GlaxoSmithKline plc. from

June 1998 to November 2002. From 1997 to 1998, Mr. Tyson served as GlaxoSmithKline’s Vice President and General Manager of Business Operations. During his14-year tenure at GlaxoSmithKline, he served in a variety of roles with broad international and domestic responsibilities, including significant management experience running two divisions: Glaxo Dermatology and Cerenex Pharmaceuticals. He was responsible for managing all sales and marketing for the U.S. operations, where he launched over 30 new products. Prior to his tenure at GlaxoSmithKline, Mr. Tyson served in a number of executive positions at Bristol-Myers Company in Operations and Research and Development. Before his tenure at Bristol-Myers, he served as a Manufacturing Manager for Procter & Gamble. He served as an Officer in the United States Army from 1974 to 1979 and spent 14 years in the United States Army Reserves. He has been IndependentNon-Executive Chairman of Icagen, formerly Caldera Pharmaceuticals, since April 1, 2014 and has been a director since October 2013. He served or serves as Director for: the Pharmaceutical Research and Manufacturing Association; BICOM; the Chief Executive Officer Roundtable for the University of California at Irvine; the Dean’s Executive Forum at Cal State Fullerton; the Health Sector Advisory Board at Duke University; the Leadership Forum of the International Society of Pharmaceutical Engineers and as a visiting lecturer at Cambridge University. He served as a Director of Valeant Pharmaceuticals International from 2004 to February 1, 2008. In 2002, Mr. Tyson received a Bicentennial Leadership Award from the United States Military Academy at West Point and was named 2007 Alumnus of the Year at Jacksonville State University. Mr. Tyson received a Master in Business Administration and Master in Public Administration from Jacksonville State University in 1979 and 1976, respectively. He is also a 1974 graduate of the United States Military Academy at West Point.

Our Board believes that Mr. Tyson’s significant operational and senior management experience in the pharmaceutical industry, as well as his extensive experience as a director on public and private boards, allow him to make valuable contributions to the Board.

Directors continuing in office with terms expiring in ~~2020.~~2023.

~~James Biehl~~David ~~has been a member of our Board since March 2017. Mr. Biehl has been a partner at the law firm of Drinker Biddle & Reath LLP (“DBR~~”) since 1998 in the Corporate and Securities group. As a corporate lawyer with over 25 years of experience representing public and private companies with structuring, negotiating and managing sophisticated securities and corporate transactional matters, he has extensive experience with federal and state securities laws, public debt and equity financings, mergers and acquisitions, corporate venture transactions, joint ventures and strategic alliances, emerging company formation and management, and corporate governance matters. Jim’s industry experience includes representing big pharma, healthcare systems, healthcare consulting firms, consumer products, and medical device companies.

Our Board of directors believes that Mr. Biehl’s experience representing healthcare and life sciences companies, as well as his legal, governance and business development counseling background, enable him to make valuable contributions to the Board.

~~David~~ Carberry has been a member of our Board since March 2017. Mr. Carberry is a retired healthcare financial executive with over 40 years of experience in the industry. Most recently, from April 2012 to June 2016, Mr. Carberry was the Chief Financial Officer of Excellis Health Solutions, LLC, a consulting and software solutions company focused on the healthcare industry. Before that, Mr. Carberry was Chief Financial Officer of Aldagen, a biopharmaceutical company, from 2008 to 2011. Mr. Carberry also served in a number of financial oversight roles within Johnson & Johnson and related divisions between 1981 and 2008, including Vice President, Finance of Independence Technology L.L.C., Johnson & Johnson/Merck Consumer Pharmaceuticals, a joint venture, and Vice President, Finance of Johnson Health Care Systems, Inc., a healthcare account management and business services provider. Mr. Carberry is a Certified Management Accountant with a BA in Accounting from LaSalle University and a MBA in Finance from Drexel University.

Our Board believes that Mr. Carberry’s deep understanding of large pharma and healthcare finance, research and development, strategy and operations enable him to make valuable contributions to the Board.

Douglas A. Michels has been a member of our Board since October 2018. Mr. Michels is the former President and Chief Executive Officer of OraSure Technologies, Inc., beginning in June 2004 and retiring in March 2018. Mr. Michels brings considerable expertise and executive leadership skills in the having nearly thirty years of experience in pharmaceutical industry having spent time with OraSure Technologies, Inc., Johnson & Johnson and Abbott Laboratories. In February 2010, Mr. Michels was appointed to the Presidential Advisory Council on HIV/AIDS. He previously served on the Board of the National Blood Foundation, the Board of the National Committee for Quality Health Care and the Coalition to Protect America’s Health Care. Mr. Michels is currently a director of West Pharmaceutical Services, Inc. (NYSE: WST), where he serves on the audit committee and as the chairman of the compensation committee. He is a past trustee for St. Luke’s University Health Network in Bethlehem, Pennsylvania, and served as a trustee at Miller-Keystone Blood Center, also in Bethlehem, Pennsylvania, until April 2019.

Our Board believes that Mr. Michel’s significant operational and senior management experience in the pharmaceutical industry, as well as his experience as a director on public and private boards, allow him to make valuable contributions to the Board.

Paul L. Sturman has been a member of our Board since March 2017. Mr. Sturman has worked in the healthcare industry in a variety of leadership positions. Mr. Sturman worked at Pfizer from January 2009 to September 2014 where he ran the Global Consumer Healthcare division, one of the largestover-the-counter healthcare products companies in the world. He also previously served at Johnson & Johnson from January 2007 to December 2008 as President of its North American Consumer Health division as well as numerous leadership roles in marketing, brand, and sales management with Warner Lambert. Since September of 2017, Mr. Sturman has served as Chief Executive Officer of Nature’s Bounty Co., a nutritional science products company. Mr. Sturman also briefly served as President and CEO of NJOY, Inc. (“NJOY”) from January 2015 to July 2016. On September 16, 2016, NJOY filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code in U.S. Bankruptcy Court in Delaware. He iswas a member of the Board of Trustees of the Foundation for Morristown Medical Center from December 2012 to December 2017, which works to advance healthcare for patients by preserving and expanding programs and services in patient care, clinical research, medical and public health education, and preventive medicine.

Our Board believes that Mr. Sturman’s extensive experience in the pharmaceutical and consumer healthcare businesses, including his extensive experience in senior management, marketing, operations and strategy allow him to make significant contributions to the Board.

The Board of Directors recommends a vote “FOR” the election of Messrs. DeGolyer and

Hoffman ~~Demurjian and DeGolyer~~ as Class I directors.

EXECUTIVE OFFICERS

The table below sets forth information with respect to our executive officers other than Messrs. Hoffman and ~~Demurjian~~Cunningham as of ~~June 25, 2018.~~July 1, 2021. Information regarding Messrs. Hoffman and ~~Demurjian~~Cunningham can be found directly above under ~~“Proposal No.1-Election~~“Election of ~~Directors.”~~Directors”.


Name	Age	Position
~~Ben R. Taylor~~James Biehl	41	~~President and Chief Financial Officer~~
~~Dr. Giuseppe Del Priore~~	5557	Chief ~~Medical~~Legal Officer and Corporate Secretary
Dr. Jonathan Eckard	4447	Chief ~~Scientific Affairs~~Business Officer
Barbara C. Galaini	63	Principal Accounting Officer and Corporate Controller
Frank Porfido	57	Chief Financial Officer
John Rothman	72	Executive Vice President of Product Development
Jan Van Tornout	65	Acting Chief Medical Officer

The following is a brief biographical summary of the experience of our executive officers:

~~Ben R. Taylor~~James Biehlhas served as the Chief Legal Officer and Corporate Secretary of Tyme since September 2018. Mr. Biehl served as a member of our Board from March 2017 to September 2018. Prior to joining the Company, Mr. Biehl had been ~~President~~a partner at the law firm of Drinker Biddle & Reath LLP since 1998 in the Corporate and ~~Chief Financial Officer since April 2017. He has~~Securities Group. As a corporate lawyer with over 1930 years of ~~life sciences~~ experience ~~in investment banking~~representing public and ~~emerging growth companies. He joined Tyme from Barclays Capital Inc., where~~private companies with structuring, negotiating and managing sophisticated securities and corporate transactional matters, he had been the Head of Commercial Pharma since February 2016. Before Barclays, Mr. Taylor spent ten years at Goldman, Sachs & Co. in various positions of increasing responsibility, most recently as Head of Emerging Pharma from August 2013 to February 2016 and~~Co-Head~~ ~~of Chinese and Southeast Asian Healthcare from January 2012 to July 2013. Mr. Taylor~~ has extensive experience ~~in pharmaceutical business models, financing~~with federal and state securities laws, public debt and equity financings, mergers and acquisitions, corporate venture transactions, joint ventures and strategic ~~transactions, with a focus on developmental~~alliances, emerging company formation and ~~midcap biopharma. In addition to investment banking, he also spent two years at a~~management, and corporate governance matters. Mr. Biehl’s industry experience includes representing big pharma, healthcare systems, healthcare consulting firms, consumer products, and medical ~~diagnosticstart-up,~~ ~~leading its finance and business development functions.~~device companies.

~~Dr.~~ ~~Giuseppe Del Priore~~ has been Chief Medical Officer since November 2015. Before joining the Company, he served as founding National Director of Gynecologic Oncology at the Cancer Treatment Centers of America (CTCA) from October 2013 to July 2015 and as its Southeastern Regional Director from October 2013 to November 2015. Dr. Del Priore also served on our Advisory Board from April 2015 to November 2015. Prior to CTCA, from January 2010 to December 2013, Dr. Del Priore was a tenured Distinguished Professor and Director of Gynecologic Oncology at the Indiana University School of Medicine in Indianapolis, where he directed its gynecologic oncology fellowship program and continued to teach for years later. He previously also served as Director of Gynecologic Oncology at New York University Downtown Hospital, Montefiore Medical Center, and Bellevue Hospital in New York City, as well as Assistant Director of Gynecologic Oncology at New York University School of Medicine. Dr. Del Priore earned his Doctor of Medicine with Distinction in Research from State University of New York Downstate Medical Center in Brooklyn and was valedictorian of his medical school class. He studied at The City University of New York’s Brooklyn College in a combined Bachelor of Arts/Doctor of Medicine Program, earning both degrees in seven years. Dr. Del Priore graduated magna cum laude with a Bachelor of Arts in Philosophy. He received his Master of Public Health in Biostatistics and Epidemiology from the University of Illinois at Chicago and completed other training at Northwestern University, Memorial Sloan Kettering, and the University of Rochester. U.S. News and World Report, Castle-Connelly, and others named Dr. Del Priore one of its “Best Doctors” multiple times. He is an active researcher and prolific writer. He has authored and published more than 200 papers, book chapters and abstracts and written three books. He has served on several committees and organizations, including appointments at the Society of Gynecologic Oncologists and the Gynecologic Oncology Group, a National Cancer Institute Cooperative Group. He is also an examiner for the American Osteopathic Association Board of Obstetrics and Gynecology, Gyn Oncology subspecialty section.

Dr. Jonathan Eckard has been the Chief Business Officer of Tyme since March 2019. Prior to that appointment, Dr. Eckard, served as the Chief Scientific Affairs Officer ~~of Tyme~~ since August 2017. Dr. Eckard has worked in the biotechnology sector and has over ten years of financial experience following the biotechnology ~~sector,~~equity capital markets, bringing to Tyme both important industry insights and an understanding of the healthcare equity markets. He was previously Chief Business and Strategy Officer of SELLAS Life Sciences, Ltd., a Bermuda-based late stage biopharmaceutical company focused on the development of novel cancer immunotherapies and therapeutics (“SELLAS”). from October 2016 to August 2017. Prior to his employment at SELLAS, Dr. Eckard worked at Barclays plc from March 2015 to

October 2016, where he was a director and senior biotechnology analyst. Prior to that, Dr. Eckard covered small- andmid-cap companies in the biotechnology and specialty pharmaceutical sectors as an equity research analyst at Citigroup Inc. ~~from July 2012 to March 2015,~~, Leerink Partners LLC ~~from April 2007 to June 2012~~ and HSBC Holdings ~~plc from July 2005 to February 2007. Dr. Eckard has received multiple accolades over the course of his career, including Institutional Investor’s “BestUp-and~~ ~~Comer” and “Rising Star.”~~plc. Prior to Dr. Eckard’s career in finance, Dr. Eckard conducted oncology research and taught at The New York University School of Medicine (“NYU Med”). Dr. Eckard earned his PhD in toxicology and carcinogenesis in 2005 and a master’s degree in toxicology in 2000 from NYU Med and a bachelor of science in biochemistry from Ohio University in 1996.

Barbara Galaini has served as the Principal Accounting Officer of Tyme since August 2018 and the Company’s Corporate Controller since April 2018. Before joining the Company, Ms. Galaini was the Chief Accounting Officer of the Americas for Avolon Holdings, a global aircraft leasing company. Prior to that she was employed at CIT Bank for more than 25 years in various financial roles, including Head of SEC Reporting and Accounting Policy, segment Chief Financial Officer and most recently as Senior Vice President and Controller of the Transportation Finance, overseeing the accounting and reporting for over $15 billion in assets. Ms. Galaini is a Certified Public Accountant, and has extensive experience in structured finance and leasing transactions, acquisitions and divestitures, and finance integration.

Frank Porfido has been the Chief Financial Officer of Tyme since June 14, 2021. He brings over 25 years of strategic financial experience, including in the pharmaceutical and biotechnology industries. Most recently

before joining Tyme, Mr. Porfido was the Vice President, Finance of UroGen Pharma Inc., a pharmaceutical company specializing in cancer and urologic diseases, since 2019. While there, he was responsible for day-to-day operations of finance and played a key role in the launch of the company’s first commercial product. Prior to that, he served in various roles of increasing responsibility at Novartis, a multinational pharmaceutical company, including serving as US CFO and Head of Global Finance and Operations of the Oncology Business Unit. Mr. Porfido is a Certified Public Accountant and received his BBA in Accounting-CPA Prep from Pace University, his MBA in Finance from Farleigh Dickinson University.

John Rothman has served as our Executive Vice President of Product Development since August 2018. Dr. Rothman has more than 30 years of experience in product development across many disciplines and markets. Prior to joining Tyme, Dr. Rothman founded and was employed by Hoffman Technologies Inc., which developed proprietary autism technology. Prior to that, he was Executive Vice President of Science and Operations of Advaxis, Inc. from 2005 to 2013 and was responsible for R&D, toxicology, regulatory, chemistry, data management, manufacturing and intellectual property. He was also a clinical scientist at the pharmaceutical companies, Schering Plough and Roche, where he was also a clinical director for a number of different therapeutic areas and senior director for all of Roche’s data acquisition, statistical analysis and report writing for all experimental and approved drugs in the Roche.

Jan Van Tornout has served as our acting Chief Medical Officer since April 1, 2021. Dr. Van Tornout brings over 25 years of medical experience in academia and industry, including over 15 years of global drug development in pharmaceutical and biotech settings and encompassing preclinical, IND, FIH, phase II-IV, (s)NDA, BLA, safety, medical affairs, clinical operations and regulatory experience. Prior to joining Tyme, Dr. Van Tornout was founder and CEO of B.IO.Pharma eConsulting, a pharmaceutical consulting firm, from March 2016 to April 2021. Before this, he was Senior Vice President and Head of Oncology for Natera, Inc., a clinical genetic testing company, between 2015 and 2016. He has led clinical management and oncology teams at Natera, INOVIO Pharmaceuticals, Astellas Pharma, Bristol Myers Squibb and Amgen and has served as a medical strategy consultant for various biotech companies including Cyclacel Pharmaceuticals, GlaxoSmithKline, Puma Biotechnology, Maverick Therapeutics, ERT, Huya Bioscience, and Gradalis.

CORPORATE GOVERNANCE

Code of Ethics

We have a Code of Business Conduct and Ethics (the “Code of Ethics”) that applies to our Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer and Corporate Controller and all other employees. The purpose of the Code of Ethics is to provide written standards that are reasonably designed to promote: honest and ethical conduct; full, fair, accurate, timely and understandable disclosure in reports and documents filed with the SEC and other public communications by the Company; compliance with applicable governmental laws, rules and regulations; prompt internal reporting of violations of the Code of Ethics; accountability for adherence to the Code of Ethics; and to deter wrongdoing. The Code of Ethics is available on our website at www.tymeinc.com. We intend to post on our website any amendments and a description of any such amendments (other than a technical, administrative, or other non-substantive amendment) to ~~or waivers~~the Code of Ethics as well as any waiver of any provision of the Code of Ethics, to the extent applicable to our Chief Executive Officer, principal financial officer or principal accounting officer or that relates to any element of the SEC’s definition of a “code of ethics.”

Our employees are also subject to the code of ethics of Insperity, Inc. (“Insperity”), the professional employer organization to which we outsource certain human resources matters. The Insperity code of ethics is designed to promote principles and values similar to our Code of Ethics.

~~Leadership; Controlled Company; Director Independence~~Leadership and Board Structure

Our Board consists of ~~Steve Hoffman, Michael Demurjian,~~David Carberry, Richard Cunningham, Donald W. DeGolyer, Steve Hoffman, Douglas A. Michels, Dr. Gerald Sokol, ~~Tommy G. Thompson,~~Paul Sturman and Timothy C. ~~Tyson, James Biehl, David Carberry and Paul Sturman.~~Tyson. The Board currently ~~combines~~separates the role of Chairman and the role of Chief Executive Officer, ~~and does not have a lead independent director position.~~with the positions being held by Steve Hoffman, ~~currently serves~~our Chief Science Officer, and Richard Cunningham, our Chief Executive Officer, respectively. In May 2021, the Board appointed Douglas A. Michels as ~~both~~Lead Independent Director. The Lead Independent Director has the responsibility of, among other duties, presiding at all meetings at which the chairman is not present, including executive sessions of our independent directors, consulting with the chairman and chief executive officer on Board and committee meeting agendas, acting as a liaison between the chairman and the independent directors and facilitating teamwork and communication between the independent directors and the chairman and management.

Our Board believes the separate roles of an executive Chairman and Chief Executive Officer, as well as a Lead Independent Director, is in ~~addition~~the best interest of stockholders because it provides the appropriate balance between strategic development and independent oversight of risk management. In coming to ~~serving as~~this conclusion, the ~~Company’s Chief Science Officer. The~~ Board ~~believes this~~considered the importance of having an interested chairperson that is familiar with our day-to-day management activities, the ~~most efficient~~scientific development behind our product candidates and ~~effective leadership structure for the Company at this time.~~our ongoing clinical trials. Mr. Hoffman is ~~one of~~ the ~~Company’s largest stockholders, and owns 26.3% of the outstanding Common Stock as of the record date. Mr. Hoffman is the~~co-founder of the Company’s precursor, Tyme, Inc., and has been the Chairman of Tyme, Inc. since its formation in 2013. The Board believes that he is uniquely qualified through his experience and expertise to set the agenda for, and lead discussions of, strategic issues for the Company at the board level. Given these qualifications, the Company does not believe an independent Chairman is beneficial at this time.

~~The Company meets~~We believe that a classified board promotes both the ~~definition~~independence of our directors and continuity in our Board. A three-year term helps ensure that the Board is comprised of experienced directors who are well-versed in our business, strategic goals, history and culture. It allows directors to develop the deep understanding of our complex business, ongoing clinical trials, and historical operations that we believe is critical to effectively overseeing our business and guiding our strategy. We also believe that a ~~“Controlled Company,” under Nasdaq Listing Rule 5615(c)(1), because its two~~staggered board promotes stockholder value in the transactional context in that it encourages any ~~co-founders,~~would-be ~~Messrs. Hoffman and Demurjian, as~~acquirer of the ~~record date, collectively beneficially own more than 50%~~Company to negotiate at arms-length with the Company to ensure the fairness and adequacy of any offer, protect stockholders against abusive tactics during a takeover process, and, as appropriate, negotiate the ~~voting power~~best possible return for all stockholders. We believe a classified board is an effective method of ~~the Common Stock~~protecting long-term stockholder interests and ~~have agreed to vote together~~value while not compromising on ~~certain matters submitted for a stockholder vote.~~ accountability.

Director Independence

The Company, therefore, is exempt from certain independence requirements of the Nasdaq rules, including the requirement to maintain a majority of independent directors on the Company’s Board as well as the requirement to maintain a nominating and corporate governance committee and a compensation committee composed entirely of independent directors. Notwithstanding the exemption, the Board has reviewed the independence of the directors under the applicable Nasdaq standards. Based upon this review, the Board has determined that Dr. Sokol and Messrs. Carberry, DeGolyer, ~~Sokol, Thompson,~~Michels, Sturman and Tyson ~~Biehl, Carberry and Sturman~~ meet the Nasdaq definition of independent and that each member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee meets the heightened independence standards under Nasdaq and SEC rules.

After review of all relevant transactions or relationships between each director, or any of his family members, and the Company, our senior management and its independent registered public accounting firm, the Board has affirmatively determined that all of our directors are independent directors within the meaning of the applicable Nasdaq listing standards, as currently in effect, excluding Messrs. Hoffman and ~~Demurjian,~~Cunningham, who serve as executive officers of Tyme. In making that determination, the Board considered that Mr. Biehl is a partner at DBR, which provided legal services to the Company in the year ended March 31, 2018, and subsequently, and is expected to continue to do so in the future. DBR has received customary compensation for these services. See “Certain Relationships and Related Party Transactions”. The Board also considered Mr. Thompson’s former service as an advisor to the Board from February 15, 2017 until his appointment to the Board on February 5, 2018, in which capacity he received no cash compensation and was awarded 68,639 options on November 22, 2017 with a two-year term, exercisable immediately at a price of $4.10 having a grant date value of $113,223, $50,723 of which represented compensation for past director service and $62,500 of which represented

~~compensation for past service as anon-director~~ ~~advisor to the Board, and determined, that this does not impair his independence.~~

Risk Oversight

Risk assessment and oversight are an important part of our governance and management processes. Our management is responsible for ourday-to-day risk management activities. The Board oversees the implementation of risk mitigation strategies by management and encourages management to incorporate risk management into our corporate strategy andday-to-day business operations. Management evaluates strategic and operational risks and conducts specific strategic planning and review sessions during the year that include a discussion and analysis of the risks facing us. Our Board is apprised of particular risk management matters in connection with its general oversight and approval of corporate matters and significant transactions. Our Board administers this oversight function directly through the Board as a whole, as well as through the Audit Committee. The Board believes its leadership structure is effective in fulfilling its role in the oversight of our risks.

Communications with Directors

Interested parties may communicate with our Board or with an individual director by writing to our Board or to the particular director and mailing the correspondence to: Tyme Technologies, Inc., ~~17 State Street – 7th Floor, New York, NY 10004,~~1 Pluckemin Way, Suite 103, Bedminster, NJ 07921, Attention: Corporate Secretary. In light of disruptions caused by the COVID-19 pandemic, we advise that you also send a copy via email to investorrelations@tymeinc.com. The Corporate Secretary will promptly relay to the addressee all communications that he determines require prompt attention and will regularly provide our Board with a summary of all substantive communications.

Director Nominations

~~We rely on Nasdaq’s controlled company exemption such that our Board does not have a standing nominating committee or a committee performing similar functions at this time. Our Board believes it~~The Nominating and Corporate Governance Committee is appropriate not to have a nominating committee because the full board effectively performs the functions of a nominating committee. Additionally, our Board believes that input from all directors in the nominating process enhances our ability to identify, evaluateresponsible for identifying, screening and select director nominees. The Board expects to constitute a nominating committee at some point in the future. Because we do not currently have a nominating committee, our full Board participates in the consideration of other nominees.

~~In searching for~~recommending qualified director candidates for election to the Board. The Board ~~the Board~~as a whole is responsible for approving nominees. The committee may solicit current directors and executives of the Company for the names of potentially qualified candidates or ask directors and executives to pursue their own business contacts for the names of potentially qualified candidates. The Board may in the future consult, but has not historically consulted, with outside advisors or retain search firms to assist in the search for qualified candidates. The Board would consider candidates nominated by stockholders, as discussed above. Once potential candidates are identified, the ~~Board~~committee reviews the backgrounds of those candidates, evaluates candidates’ independence from the Company and potential conflicts of interest (including actual or potential competition with the Company) ~~and~~, determines if candidates meet the qualifications desired ~~by the Board~~ for election as a ~~director.~~director, and makes a recommendation to the whole Board. The ~~Board~~committee considers the diversity of directors as part of the overall mix of factors when identifying and evaluating candidates for the Board. The Company considers diversity broadly to include differences of viewpoint, professional experience, individual characteristics (including age, race, ethnicity, gender, LGBTQ+ status) and qualities and skills, resulting in naturally varying perspectives among the directors and individual skills that complement the full Board. In particular, the ~~Board~~committee seeks candidates ~~that~~who have a depth of experience and skills in areas relating to biopharmaceutical development, commercialization, strategy, and regulatory matters.

The committee is actively seeking new Board talent and may engage a third-party search firm to help identify and evaluate potential candidates.

The committee also will consider candidates for director recommended by stockholders so long as the recommendations comply with our Certificate of Incorporation andBy-Laws and applicable laws, rules and regulations, including those promulgated by the SEC. The ~~Board~~committee will evaluate such recommendations in

accordance with our Certificate of Incorporation andBy-Laws, and such other criteria it deems appropriate. Stockholders wishing to recommend a candidate for nomination should comply with the procedures set forth in the section above entitled “Questions andAnswers-How do I recommend a director nominee?”

Board Composition and Diversity

The Board is comprised of directors with different professional experiences, skills and viewpoints who provide unique contributions to the development and oversight of the Company. The director biographies included in this Proxy Statement indicate each director’s experience, qualifications, attributes and skills that led the Board to conclude that each should continue to serve as a member of our Board. Our Nominating and Corporate Governance Committee and Board believe that the directors have each have had substantial achievement in their professional and personal pursuits and possess the background, talents and experience that our Board desires and that will contribute to the best interests of our Company, align with our long-term strategy and protect long-term stockholder value. As further discussed below, Messrs. Carberry, DeGolyer, Michels and Tyson serve on our Strategic Planning Committee, dedicating more of their time and expertise to assist the Board with its responsibilities for the Company’s mission, vision and strategic direction.

While the Company does not have a formal policy on diversity, as part of its process to seek new Board talent, the Nominating and Corporate Governance Committee has resolved to place significant weight on diversity characteristics, such as race, gender and LGBTQ+ status when considering future board candidates. The Nominating and Corporate Governance Committee is actively seeking diverse candidates and is making an effort to add at least one such candidate to the Board in fiscal year 2022. See “Director Nominations” above for how the Board considers diversity of directors as part of the overall mix of factors when identifying and evaluating candidates for the Board.

Policies and Procedures for Related Person Transactions

~~Pursuant~~Although the Company does not have a formal, written related person transaction policy, pursuant to its charter, our Audit Committee is responsible for reviewing and approving, as appropriate, all transactions with related persons. In reviewing and approving any such transactions, our Audit Committee considers all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction and the extent of the related person’s interest in the transaction.

Board of Directors Meetings and Committees

There were ~~eight~~fifteen meetings of the Board during the fiscal year ended March 31, ~~2018.~~2021. During fiscal year ~~2018,~~2021, ournon-management directors ~~did not meet~~met nine times in executive session. During the fiscal year ended March 31, ~~2018,~~2021, each director attended at least 75% of the total number of meetings of the Board and the committees on which he served during fiscal year ~~2018.~~2021.

While we do not maintain a formal policy regarding director attendance at annual meetings of ~~security holders,~~stockholders, we expect that, absent compelling circumstances, directors will attend such meetings, including the Annual ~~Meeting, which is~~Meeting. All of our ~~first~~then-current directors attended the annual meeting ~~of stockholders.~~in 2020.

Our Board has an ~~audit committee~~Audit Committee, a Compensation Committee, a Nominating and Corporate Governance Committee and a ~~compensation committee,~~Strategic Planning Committee, each of which has the composition and responsibilities described below. Members serve

on these committees for such term or terms as our Board may determine or until their earlier resignation or death. ~~Both~~Each of these committees are governed by a written charter, which are posted on our website at www.tymeinc.com.

In addition, Messrs. Carberry, DeGolyer, Michels and Tyson serve on the Strategic Planning Committee of the Board and generally target to meet with management on a quarterly basis or more frequently as appropriate. The committee was organized in November 2018 and formally established by the Board in May 2020. Mr. Michels serves as the chairman of the committee, which assists the Board with its responsibilities for the Company’s mission, vision and strategic direction and is provided updates on the Company’s progress on various initiatives.

From time to time, our Board may also establish other special committees when necessary to address specific issues.

Audit Committee

We have a separately-designated standing audit committee established in accordance with Section 3(a)(58)(A) of the Exchange Act. Our Audit Committee consists of Messrs. Carberry, DeGolyer and Tyson, with Mr. Carberry serving as the Chair. ~~Before Mr. DeGolyer’s appointment in May 2018, Mr. Sturman served on the Audit Committee.~~ The Audit Committee met ~~five~~four times during fiscal year ~~2018.~~2021. Our Board has affirmatively determined that Messrs. Carberry, DeGolyer and Tyson ~~as well as Mr. Sturman,~~ each meet the definition of “independent director” for purposes of serving on an audit committee under Rule10A-3 under the Exchange Act and the Nasdaq rules. The Board has determined that Mr. Carberry qualifies as an “audit committee financial expert,” as such term is defined in Item 407(d)(5) of RegulationS-K.

The Audit Committee is primarily responsible for selecting, retaining and overseeing the work of our independent registered public accounting firm, overseeing the audit, reviewing our annual audited and interim financial results and providing risk and compliance oversight. Among other things, this includes:

To select, retain, compensate, oversee and terminate, if necessary, any registered public accounting firm engaged for the purpose of preparing or issuing an audit report;

To review with management and the Company’s independent auditors: critical accounting policies and practices used in an audit, any major issues regarding accounting principles and financial statement presentation and any audit problems or difficulties;

To review with management and the Company’s independent ~~auditors~~auditors: the adequacy and effectiveness of the Company’s financial reporting processes, internal control over financial reporting and disclosure controls and procedures, including any significant deficiencies or material weaknesses;

To review and discuss with the Company’s independent auditors and management the Company’s annual audited financial statements (including the related notes); and

To review and discuss with management the risks faced by the Company and the policies, guidelines and process by which management assesses and manages the Company’s risks and the steps management has taken to monitor, minimize and control such exposures.

Compensation Committee

Our Compensation Committee was established in March 2018 and consists of Messrs. ~~Sturman,~~ Carberry, DeGolyer and ~~Thompson,~~Michels, with Mr. ~~Carberry~~DeGolyer serving as the Chair. The Compensation Committee met ~~for the first time in April 2018, after our~~eleven times during fiscal year ~~end.~~2021. This committee oversees compensation and benefits policies and programs for the Company, including compensation of the Company’s executive officers andnon-employee directors. Among other things, its duties include:

To annually review, and ~~approve annually~~recommend to the Board for approval, the corporate goals and objectives applicable to the compensation of the CEO and evaluate at least annually the CEO’s performance in light of those goals and objectives;

To review and approve the compensation of all executive officers other than the ~~CEO;~~CEO and to review, and recommend to the Board for approval, the corporate goals and objectives applicable to the compensation of all executive officers;

To review and approve and, when appropriate, recommend to the Board for approval, any employment agreements and any severance arrangements or plans;

To review all director compensation and benefits for service on the Board and Board committees and to recommend any changes to the Board as necessary;

To review and recommend to the Board for approval the frequency with which the Company will conduct ~~Say on Pay Votes,~~Say-on-Pay votes, taking into account the results of the most recent stockholder advisory vote on frequency of ~~Say on Pay Votes~~Say-on-Pay votes required by Section 14A of the Exchange Act, and review and approve the proposals regarding the ~~Say on Pay Vote~~Say-on-Pay vote and the frequency of the ~~Say on Pay Vote~~Say-on-Pay vote to be included in the Company’s proxy statement; and

To oversee engagement with stockholders and proxy advisory firms on executive compensation matters.

In connection with the performance of its duties, the Compensation Committee has (i) unrestricted access to and assistance from the officers, employees and independent auditors of the Company and such resources and support from the Company as the Compensation Committee deems necessary or desirable, and (ii) the authority to employ, at the expense of the Company, such experts and professionals as the Compensation Committee deems necessary or desirable from time to time.

The Compensation Committee ~~Interlocks and Insider Participation~~

Messrs. Sturman, Carberry and Thompson have served on the Compensation Committee since its formation in March 2018; before that time, the Company did not have a compensation committee. No member of the Compensation Committee during 2018: (i) has ever been an officer or employee of the Company ormay also delegate any of its ~~subsidiaries, or (ii) had any relationship~~responsibilities to a subcommittee as it may deem appropriate in its sole discretion.

Nominating and Corporate Governance Committee

Our Nominating and Corporate Governance Committee was established in March 2019 and consists of Messrs. Michels, Sturman and Tyson, with Mr. Michels serving as the ~~Company or any of its subsidiaries~~Chair. The Nominating and Corporate Governance Committee met four times during ~~2018 that would require disclosure under Item 404~~fiscal year 2021. This committee is responsible for determining the qualifications, qualities, skills, and other expertise required to be a director and to make recommendations to the Board regarding the selection and approval of the ~~SEC’s RegulationS-K.~~nominees for director to be submitted to a stockholder vote at the annual meeting of stockholders. It is also responsible for periodically reviewing the Board’s committee structure and composition and to make recommendations to the Board regarding the appointment of directors to serve as members of each committee and committee chairmen. Among other things, its duties include:

~~During~~

To review the Company’s corporate governance practices;

To develop and recommend corporate governance guidelines for Board approval;

To develop the process for evaluating directors before nomination for reelection; and

To determine the overall qualifications required to be a director.

Strategic Planning Committee

Our Strategic Planning Committee was organized in November 2018 ~~none~~and formally established by the Board in May 2020. It consists of ~~our executive officers served as a director or member~~Messrs. Carberry, DeGolyer, Michels and Tyson. The Strategic Planning Committee met three times in fiscal year 2021. This committee assists the Board in monitoring the development and implementation of the ~~Compensation Committee (or~~Company’s stategy and strategic plan. Among other things, its duties include:

To oversee the implementation of the Company’s strategy, strategic plan and related initiatives;

To review with management the process for development, approval and modification of the Company’s strategy and strategic plan;

To review with management the key issues, options and external developments impacting the Company’s strategy;

To report regularly to the Board ~~committee performing equivalent functions or, in~~and facilitate an annual review of the ~~absence~~Company’s strategy and strategic options;

To assure that the Board has the opportunity for timely and thorough review of ~~any such committee,~~ the ~~entire Board)~~Company’s strategy development and strategic plan;

To meet with management periodically to monitor the Company’s performance and ensure the Board is regularly apprised of ~~any other entity, one~~the Company’s progress with respect to implementation of ~~whose executive officers is or has been a director of our Company or a member of our Compensation Committee.~~the approved strategy; and

To identify and evaluate corporate development opportunities.

DIRECTOR COMPENSATION

The Company has adopted a director compensation policy fornon-employee directors. Under the current compensation policy, each of ournon-employee directors is entitled to receive annual cash compensation in the amount of $50,000, to be paid on a quarterly basis, as well as stock option awards as follows:

•

Upon an initial election of a director to the Board, each new director will receive a grant of options to purchase 100,000 shares of our Common Stock under our 2016 Stock Option Plan for Non-Employee Directors, as amended and restated May 24, 2018 (the “2016 Plan”), which shares will vest in equal quarterly increments over a three-year period from the date of grant rather than over a one-year period; and

An annual grant of options to purchase 65,000 shares of Common Stock under ~~our~~the 2016 ~~Stock Option Plan for~~Plan. The award vests in equal quarterly increments over a ~~Non-Employee~~one-year ~~Directors (the “2016 Plan”).~~ period from the date of grant.

From time to time, ournon-employee directors have in the past deferred and may in the future defer the right to receive cash payable pursuant to ournon-employee director compensation policy to conserve cash resources. In the future, they may elect to receive the cash award in the form of stock options also to conserve cash reserves.

~~On May 24, 2018, the Compensation Committee~~Directors serving on a committee are also ~~conducted a review of the Company’s director~~entitled to additional cash compensation ~~policy, in consultation with the independent compensation consulting firm Pearl Meyer & Partners (“Pearl Meyer~~”). The Compensation Committee’s initial findings were that the Company’s director equity compensation was meaningfully below the median of peer biotech companies. In addition, the Company did not provide additional compensation for service on Board committees, as is common among the Company’s biotech peers. In connection with the review, and upon the recommendation of the Compensation Committee, the Board approved changes to the director compensation program, such that the program now consists of the following:follows:

~~Directors’~~


Committee		Annual Cash Retainer
Audit		Chair: $15,000 Member: $7,500
Compensation		Chair: $12,500 Member: $6,250
Nominating and Corporate Governance		Chair: $8,250 Member: $4,125
Strategic Planning⁽¹⁾		Chair: $8,250 Member: $4,125

(1)	Compensation for the Strategic Planning Committee was approved and began on May 21, 2020. Actual amounts received by the committee members were prorated for the portion of fiscal year 2021 following approval of such compensation.

The lead independent director is also entitled to an additional annual cash retainer ~~will remain $50,000;~~

~~The annual grant~~ of ~~options to purchase shares of Common Stock as compensation for director service will be increased from 10,000 to 50,000 options;~~

~~A grant of 100,000 options will be awarded upon the initial election of a director to the Board;~~

~~Annual cash retainers will be implemented for service on Board committees; and~~

~~Options awarded will vest in equal quarterly increments over aone-year~~ ~~period from the date of grant.~~

~~See “Compensation Discussion & Analysis” for further identification of the peer biotech companies that were considered as part of this benchmarking analysis.~~$25,000.

Director Compensation Table

The table below includes information about the compensation paid tonon-employee directors with respect to the fiscal year ending March 31, ~~2018.~~2021. Messrs. Cunningham and Hoffman, ~~and Demurjian,~~ the ~~only~~ Company employees on the Board, do not receive any ~~director~~ compensation for Board service.

Name
   Fees Paid in Cash
($)    Option Awards(1)
($)    All Other
Compensation
($)    Total
Compensation
($)
Dr. Gerald Sokol
   50,000    —      —      50,000
Timothy C. Tyson⁽²⁾
   50,000    —      —      50,000
Paul L. Sturman⁽²⁾
   50,000    —      —      50,000
James Biehl⁽²⁾
   50,000    —      —      50,000
David Carberry⁽²⁾
   50,000    —      —      50,000
Tommy G. Thompson⁽³⁾
   12,500    —      62,500    75,000


Name⁽¹⁾	Fees Paid or Earned in Cash ($)		Option Awards⁽²⁾($)		All Other Compensation ($)			Total Compensation ($)
David Carberry		74,802		55,265		—			130,067
Donald W. DeGolyer		73,552		55,265		—			128,817
Douglas A. Michels		70,163		55,265		—			125,428
Dr. Gerald Sokol		50,000		55,265		15,000	⁽³⁾		120,265
Paul L. Sturman		54,125		55,265		—			109,390
Timothy C. Tyson		64,604		55,265		—			119,869

(1)	The table immediately below indicates each director’s outstanding option awards as of the fiscal year end.

(2)

This column lists the aggregate grant date fair value of options awarded to directors pursuant to the ~~2015 Equity Incentive~~2016 Plan, computed in accordance with FASB Accounting Standards Codification (ASC) Topic ~~718, applying~~718. These values have been determined based on assumptions set forth in Note 13 to our consolidated financial statements included in our Annual Report on Form 10-K for the ~~same model and assumptions that the Company applies for financial statement reporting purposes.~~year-ended March 31, 2021.

~~(2)~~(3)

~~Fees~~

Dr. Sokol was paid these fees in ~~cash includes the amount of accrued but unpaid cash fees payable under~~connection with his services on the Company’s ~~director compensation program foregone by thenon-employee~~ ~~directors~~Science Development Committte. That committee was discontinued in lieu of options granted on November 22, 2017. Messrs. Carberry, Sturman and Biehl received 22,270, 14,880 and 22,270 options in lieu of $36,500 in accrued cash fees, respectively. Mr. Tyson received 14,880 options in lieu of $36,500 of accrued cash fees with respect to fiscal year 2018 as well as 36,078 options in lieu of $88,500 of accrued cash fees with respect to prior year periods.

April 2021.

~~(3)~~

Served the Board from May 9, 2016 through February 15, 2017. From February 15, 2017 until he rejoined the Board on February 5, 2018, Mr. Thompson served as Special Advisor to the Board. All Other Compensation reflects the grant date fair value of options, calculated in accordance with footnote one above, granted as compensation of consulting services as Special Advisor to the Board on November 22, 2017. See “Corporate Governance – Leadership; Controlled Company; Director Independence” for information on compensation he received as a special advisor.

Outstanding Equity Awards forNon-Employee Directors as of March 31, ~~2018~~2021

The following table sets forth information regarding unexercised stock options for each Director outstanding as of March 31, ~~2018.~~2021. We have not awarded stock grants or other equity incentive awards and as such have not made any disclosures regarding such awards.


Name	Number of Securities Underlying Unexercised Options Exercisable (#)		Number of Securities Underlying Unexercised Options Unexercisable (#)		Option Exercise Price ($)		Option Expiration Date		Number of Securities Underlying Unexercised Options Exercisable (#)		Number of Securities Underlying Unexercised Options Unexercisable (#)		Option Exercise Price ($)		Option Expiration Date
David Carberry										25,000		—		2.95		03/28/2027
										75,000		—		2.90		05/24/2028
										50,000		—		2.33		08/26/2028
										50,000		—		1.18		08/22/2029
										32,500		32,500		1.22		8/19/2030
Donald W. DeGolyer										100,000		—		2.90		05/24/2028
										50,000		—		2.33		08/26/2028
										50,000		—		1.18		08/22/2029
										32,500		32,500		1.22		8/19/2030
Douglas A. Michels										145,833		—		2.71		10/01/2028
										50,000		—		1.18		08/22/2029
										32,500		32,500		1.22		8/19/2030
Dr. Gerald Sokol		25,000		—		8.75		05/09/2026		25,000		—		8.75		05/09/2026
Dr. Gerald Sokol										75,000		—		2.90		05/24/2028
										50,000		—		2.33		08/26/2028
										50,000		—		1.18		08/22/2029
										32,500		32,500		1.22		8/19/2030
										14,880		—		4.10		11/21/2022
Paul L. Sturman										25,000		—		2.90		02/24/2027
										75,000		—		2.90		05/24/2028
										50,000		—		2.33		08/26/2028
										50,000		—		1.18		08/22/2029
										32,500		32,500		1.22		8/19/2030
		25,000		—		8.75		05/09/2026		50,958		—		4.10		11/21/2022
		50,958		—		4.10		11/22/2022
Paul L. Sturman		25,000		—		2.90		02/24/2027
		14,880		—		4.10		11/22/2022
James Biehl		25,000		—		2.95		03/28/2027
		22,270		—		4.10		11/22/2019
David Carberry		25,000		—		2.95		03/28/2027
		22,270		—		4.10		11/22/2019
Tommy G. Thompson		25,000		—		8.75		05/09/2026
		68,639		—		4.10		11/22/2019
Timothy C. Tyson										25,000		—		8.75		05/09/2026
										75,000		—		2.90		05/24/2028
										50,000		—		2.33		08/26/2028
										50,000		—		1.18		08/22/2029
										32,500		32,500		1.22		8/19/2030

OWNERSHIP OF COMMON STOCK

Security Ownership of Certain Beneficial Owners and Management

As of ~~June 25, 2018,~~July 1, 2021, the record date, the Company had ~~101,226,479~~172,206,894 shares of Common Stock outstanding. The following tables set forth certain information regarding the ownership of shares of Tyme’s Common Stock as of the close of business on that date, by:

each person known by Tyme to beneficially own more than 5% of the outstanding shares of each class of our stock;

each of our directors;

each of our Named Executive Officers (as defined under ~~“Compensation Discussion & Analysis”~~“Executive Compensation” below) who currently serve in such roles; and

all of our directors and executive officers as a group.

Beneficial ownership data below includes stock options and warrants that are exercisable within sixty days after ~~June 25, 2018~~July 1, 2021 (“Currently Exercisable”).

The following table sets forth certain information regarding the beneficial ownership of the Common Stock for each director and ~~named executive officer~~Named Executive Officer for fiscal year ~~2018~~2021 and all directors and executive officers of the Company as a group. The number of shares beneficially owned is as of ~~June 25, 2018.~~July 1, 2021.

   Amount and Nature
of Beneficial Ownership
Name and Address of Beneficial Owner
   Common
Stock
Owned    Options Exercisable
Within 60 Days of
Record Date    Percentage
Named Executive Officers and Directors⁽¹⁾
Steve Hoffman⁽²⁾
   26,644,528    375,000    26.6 %
Michael Demurjian⁽²⁾
   26,651,655    375,000    26.6 %
Ben R. Taylor
   0    529,957    0.5 %
Giuseppe Del Priore
   2,582    331,834    0.3 %
Dr. Gerald Sokol
   5,865    100,000    0.1 %
Dr. Jonathan Eckard
   0    50,000    *
Timothy C. Tyson
   5,865    150,958    0.2 %
David Carberry
   0    122,270    0.1 %
Paul Sturman
   0    102,380    0.1 %
James Biehl⁽³⁾
   20,150    1,102,270    1.1 %
Tommy G. Thompson⁽⁴⁾
   105,865    168,639    0.3 %
All directors and executive officers as a group (eleven persons)⁽⁵⁾
   53,436,510    2,428,308    53.9 %


	Amount and Nature of Beneficial Ownership
Name and Address of Beneficial Owner	Common Stock Owned		Options Exercisable Within 60 Days of Record Date		Percentage
Named Executive Officers and Directors⁽¹⁾
James Biehl⁽²⁾		65,150		1,882,400		1.1	%
David Carberry		50,000		265,000		0.2	%
Richard Cunningham		—		375,000		0.2	%
Donald W. DeGolyer		—		265,000		0.2	%
Jonathan Eckard		—		1,171,769		0.7	%
Steve Hoffman⁽³⁾		23,992,748		500,000		14.2	%
Douglas A. Michels⁽⁴⁾		60,000		260,833		0.2	%
Frank L. Porfido⁽⁵⁾		—		—		—
Dr. Gerald Sokol		5,865		265,000		0.2	%
Paul Sturman		—		279,880		0.2	%
Timothy C. Tyson⁽⁶⁾		5,865		315,958		0.2	%
All directors and executive officers as a group (fourteen persons)⁽⁷⁾		24,191,437		5,701,751		16.9	%

*	~~Less than 0.1%.~~

(1)	The address of each of the beneficial owners identified herein is ~~17 State Street – 7th Floor, New York, NY 10004.~~1 Pluckemin Way, Suite 103, Bedminster, NJ 07921.

(2)	Includes ~~shares of common stock for which this holder possesses sole voting power, but which are subject to a Currently Exercisable(non-Company)~~ ~~option through which a fellow director, Mr. Biehl, may acquire certain shares. See Footnotes 3 and 5 hereto.~~

~~(3)~~

~~Includes 20,000 shares owned directly and~~ 150 shares ~~owned~~held indirectly by Mr. Biehl’s spouse. Mr. Biehl also owns Currently Exercisable options to purchase 490,000 shares from each of Mr. Hoffman and Mr. Demurjian with an expiration date of March 2027. See footnote 3 hereto.

(3)

Includes shares of Common Stock for which this holder possesses sole voting power, but which are subject to a Currently Exercisable (non-Company) option through which a fellow executive officer, Mr. Biehl, may acquire 490,000 shares from Mr. Hoffman with an expiration date of March 2027. See footnote 2 hereto.

(4)

~~Includes 5,685~~

Mr. Michels holds his Common Stock in a joint account with his spouse and, accordingly, shares ~~owned directly and 100,000 shares owned by Thompson Family Investments LLC, a family-owned investment vehicle over which Mr. Thompson holds~~ voting and investment ~~power.~~power over such shares.

(5)	Frank Porfido joined the Company as Chief Financial Officer on June 15, 2021. He was not a named executive officer or director for fiscal year 2021 but is shown here for informational purposes.

(6)	Mr. Tyson’s spouse, as co-trustee of the Tyson Revocable Trust, shares voting and investment power over 5,865 shares of Common Stock held in a trust account.

(7)

Shares owned by Mr. Hoffman subject to the~~non-Company~~ ~~options~~ option described in footnotes 2 and 3 are counted once as currently owned shares, and not double-counted as Currently Exercisable options for purposes of this calculation. As described in footnote 2, Mr. Biehl has another option through which he may acquire 490,000 shares from a non-affiliate Tyme stockholder with an expiration date of March 2027, which shares are included as Currently Exercisable options for purposes of this calculation.

The following table sets forth certain information regarding the beneficial ownership of the Common Stock as of ~~June 25, 2018~~July 1, 2021 for each person known to the Company who beneficially owns more than five percent of the Company’s outstanding Common Stock, the name and address of such beneficial owner and the percentage such shares comprise of the outstanding Common ~~Stock.~~Stock, other than Mr. Hoffman, who is discussed in table directly above.


						Amount and Nature of Beneficial Ownership
Name and Address of Beneficial Owner	Common Stock Owned		Percentage			Common Stock Owned		Options Exercisable Within 60 Days of Record Date		Percentage
Christopher F. Brown⁽¹⁾ 390 Park Avenue, 7th Floor New York, NY 10022		9,683,218		9.6	%
Michael Demurjian⁽¹⁾ 157 Broad Street, Suite 304 Red Bank, NJ 07701							24,478,546		500,000		14.2	%
Eagle Pharmaceuticals, Inc.⁽²⁾ 50 Tice Boulevard, Suite 315 Woodcliff Lake, NJ 07677							10,000,000		—		5.8	%

(1)

Based on a Schedule 13G/A filed with the SEC on February 14, 2020 by Michael Demurjian, reflecting holdings as of January 7, 2020, Mr. Demurjian’s Form 4 filed on June 28, 2021, as well as the Company’s records subsequent those dates. Mr. Demurjian’s ownership includes 490,000 shares of Common Stock for which this holder possesses sole voting power, but which are subject to a currently exercisable (non-Company) option through which Mr. Biehl may acquire such shares. As noted in footnote 7 to the table directly above, these shares are also reflected as Currently Exercisable options for purposes of the calculation of beneficial ownership of the Company’s directors and officers as a group.

(2)

Based on a Schedule 13G filed with the SEC on ~~April 25, 2018~~January 17, 2020, by ~~Christopher F. Brown~~Eagle Pharmaceuticals, Inc. (“Eagle”) reflecting holdings as of ~~November 3, 2017~~January 7, 2020. The Company issued and ~~the Form 4 filed by Christopher F. Brown on April 25, 2018 reflecting holdings as of February 28, 2018 and subsequent confirmation from the beneficial owner. These securities include 2,518,592~~sold these shares owned by GEM Global Yield Fund LLC SCS and 1,250,000 shares owned by Gem Investments America LLC, each of which Mr. Brown is manager. Mr. Brown has sole voting and dispositive power over the accounts.to Eagle pursuant to a Securities Purchase Agreement, dated January 7, 2020.

DELINQUENT SECTION 16(a) ~~BENEFICIAL OWNERSHIP~~REPORTS

~~REPORTING COMPLIANCE~~

Based solely on (i) our review of reports submitted to us during and with respect to the year ended March 31, ~~2018,~~2021, filed with the SEC pursuant to Section 16(a) of the Exchange Act, including any amendment thereto and (ii) written representations of our directors, executive officers and certain beneficial owners of more than 10% of our Common Stock, we believe that, with the following exceptions, all reports required to be filed under Section 16(a) of the Exchange Act, with respect to transactions in our equity securities through March 31, ~~2018,~~2021, were filed on a timely basis, except for the ~~sale~~grant of ~~400~~an option to purchase 300,000 shares of Common Stock ~~by Mr. Demurjian~~to Dr. Rothman on ~~February 13, 2018,~~August 18, 2020, which was reported on ~~February 16, 2018. Additionally, Christopher F. Brown reported~~August 24, 2020, as well as the initial statement of beneficial ownership ~~6,583,260~~of Dr. Van Tornout upon his appointment on April 1, 2021 and three stock purchases by Dr. Van Tornout on April 5, 6, and 7, 2021 totaling 1,809 shares of ~~our~~ Common Stock, as of November 3, 2017 on April 25, 2018. Mr. Brown also acquired 1.25 million shares of our Common Stock on January 12, 2018 and an additional 1.25 million shares of our Common Stock on February 28, 2018, bothall of which were reported on April ~~25, 2018.~~14, 2021.

EXECUTIVE COMPENSATION ~~DISCUSSION AND ANALYSIS~~OVERVIEW

Tyme is a “smaller reporting company” as defined by the SEC, and is therefore is not required to provide, and does not purport to provide, all of the disclosures required for a “Compensation and Discussion Analysis” as set forth in rules promulgated by the SEC. The Company is, however, providing a brief overview of its executive compensation program in order to aid its stockholders’ understanding of how its business and performance affects executive compensation decisions.

Objectives of our Compensation Program

Our compensation program has been designed to attract, motivate and retain quality executive officers who will manage and lead the Company and will advance us toward achievement of our ~~clinical~~corporate and ~~business development~~strategic goals. The program is also intended to be fair and equitable to the Company’s ~~employees~~executive officers and stockholders. We also strive to increase the value of the Company, align the interests of our executive officers with those of our stockholders, and to reward our executive ~~employees,~~officers, at reasonable cost, for achievements and advances of the Company’s goals.

General

Our executive officer compensation program ~~has consisted mainly~~consists of ~~base salary, discretionary bonuses,~~the following elements:

Base salary;

Cash Incentive Bonus Plan;

Stock option awards; and ~~discretionary stock option awards, in addition to customary~~

Employee benefits.

The amounts of compensation awarded for each element of the Company’s compensation program (i.e., base salary, bonuses and stock options) are reviewed in connection with the Company’s ~~performance, but are subjective and not based on any formula or anypre-determined~~ ~~or other objective criteria.~~

~~Key compensation elements~~

~~Base salary;~~

~~Discretionary cash bonuses;~~

~~Discretionary stock option awards; and~~

~~Employee benefits.~~

performance. Each of these elements is described in more detail below. In May 2018, we engaged an independent compensation consultant, Pearl Meyer to help perform a comprehensive review of our executive compensation practices and policies. As a result of this review, we ~~plan to make~~implemented several changes to our compensation ~~structure, as more fully described under “Recent Developments” below.~~structure. To date, compensation has generally been determined based on negotiations with employees during the hiring process and available resources. Pearl Meyer was again engaged as an independent compensation consultant in fiscal year 2021. As we continue to review our policies with Pearl Meyer, we ~~expect~~have continued to formalize and further develop our approach to compensation and to implement compensation policies ~~which may include policies on: allocations between long-term and currently paid compensation; allocations between cash andnon-cash~~ compensation; bases for allocating various types of long-term awards; methodologies for setting compensation decisions, including specific corporate and individual performance items; the relationship between prior realized compensation against other elements of compensation; and tax and accounting implications. We may also establish executive equity ownership guidelines and consider these when making compensation decisions.going forward.

The Role of the Board, the Compensation Committee and Management

We established a Compensation Committee in March 2018. Before the establishment of the Compensation Committee, our full Board, in consultation with the Chief Executive Officer, determined compensation of our executive officers, except that neither Mr. Hoffman, our Chief Executive Officer, nor Mr. Demurjian, our Chief Operating Officer, was involved in the approval of his own compensation.

~~Currently, the~~Our Compensation Committee is responsible for determining the recommended compensation of our ~~named~~ executive officers, including our Named Executive Officers (defined further below), except our Chief Executive Officer. The Compensation Committee annually evaluates the CEO’s performance and Tyme’s performance against its pre-established goals and makes recommendations to the independent members of the Board about the CEO’s performance and compensation.

The Board then considers the Compensation Committee’s recommendations as part of its review and approval of the CEO’s compensation. The members of the Compensation Committee are currently Messrs. ~~Carberry~~DeGolyer (chairman), ~~Thompson~~Carberry and ~~Sturman.~~Michels. Each of the current members is an “independent director” under Nasdaq listing standards and a“Non-Employee Director” within the meaning of Section 16 of the Exchange Act.

The Compensation Committee advises our Board concerning the Company’s compensation philosophy and policies, in general, and, in particular, reviews and approves, or recommends to the Board for review and

approval, the compensation of our Chief Executive Officer and other ~~named~~ executive officers and of members of the Board. In conducting its work, the Compensation Committee consults with the Chief Executive Officer, other members of management, and may consult third-party compensation consultants. Recommendations and decisions made by the Compensation Committee are reported to the full Board for approval or ratification, as appropriate.

Compensation Consultant Role in Executive Compensation

While the Compensation Committee or Board ultimately makes all executive compensation decisions, the Compensation Committee engages the services of outside advisors for assistance. Since 2018, the Compensation Committee has directly engaged Pearl Meyer as its independent compensation consultant.

The Compensation Committee has utilized Pearl Meyer throughout these periods to provide independent, objective analysis, advice and information and to generally assist the Compensation Committee in the performance of its duties. The Compensation Committee will typically request information and recommendations directly from the compensation consultant as it deems appropriate to structure and evaluate Tyme’s compensation programs, practices and plans. As part of ~~our Board’s risk oversight responsibilities, our~~its engagement, at the direction of the Compensation Committee, ~~reviews~~the compensation consultant will work, and exchange information, with the Company’s ~~compensation~~internal legal counsel in its work on the Compensation Committee’s behalf. The Compensation Committee assesses the compensations consultant’s independence each year, considering the amount of fees paid to the consultant, the consultant’s policies designed to prevent conflicts of interest, any stock owned by the consultant, and ~~practices as generally applicable~~other factors deemed relevant to our employees and discusses with management risks created by such policies and practices. Based on that review and discussions with management, and taking into consideration Tyme’s risk assessment and risk management policies and procedures, we believe that our compensation policies and procedures do not encourage excessive or unnecessary risk-taking and that the ~~level of risk that they do encourage is appropriate.~~committee.

Elements of Compensation

Base Salary

Annual base salaries compensate our executive officers for fulfilling the requirements of their respective positions and provide them with a level of cash income predictability and stability with respect to a portion of their total compensation. We believe that the level of an executive officer’s base salary should reflect the executive’s performance, experience and breadth of responsibilities, our understanding of salaries for similar positions within our industry and any other factors relevant to that particular job.

Base salaries are typically negotiated at the outset of an executive’s employment. Salary levels are considered annually as part of our performance review process, but also in cases including promotion or other change in the job responsibilities of an executive officer. For ~~named executive officers,~~Named Executive Officers, initial base salaries generally are established in connection with negotiation of an offer of employment and employment agreement. Increases in base salary have several elements. In addition to promotion and increased responsibilities, merit and Company-wide general increases are also taken into consideration. Salaries of our ~~named executive officers~~Named Executive Officers for fiscal year ~~2018~~2021 and certain prior years are also reported in the Summary Compensation Table.

The following table shows the base salary for each of our Named Executive Officers for fiscal 2020 and fiscal 2021 and as approved for fiscal 2022:


Name	2020		Increase			2021		Increase			2022
Richard Cunningham		⁽¹⁾		⁽¹	⁾	$	550,000		2.36	%	$	563,000
Steve Hoffman	$	550,000		3.5	%	$	569,250		—		$	500,000	⁽²⁾
James Biehl		⁽²⁾		⁽²	⁾	$	465,750		2.0	%	$	475,065
Jonathan Eckard		⁽²⁾		⁽²	⁾	$	400,000		3.0	%	$	412,000

(1)	Mr. Cunningham joined the Company in fiscal year 2021.

(2)	Because such executive was not a Named Executive Officer for the fiscal year 2020, as permitted by SEC rules and guidance, his 2020 compensation is not disclosed in the table above.

(3)	In connection with his stepping down as Chief Executive Officer in November 2020, Mr. Hoffman agreed to reduce his salary to $500,000 beginning in fiscal year 2022 and $450,000 beginning in fiscal year 2023.

Cash Incentive Plan

We have a Cash Incentive Plan to motivate and reward our executives for achievements related to corporate performance for each fiscal year. Each year, the Board, after recommendation by the Compensation Committee, approves:

Corporate performance measures and goals;

Target incentive bonus opportunity for each executive officer, including each Named Executive Officer, defined as a percentage of his or her annual salary;

Funding levels for actual Cash Incentive Plan awards; and

Individual awards for the Named Executive Officers, except for the CEO’s award, which is approved by the Board.

Each year, the Board, upon the recommendation of the Compensation Committee, establishes major corporate objectives for the coming fiscal year related to clinical activities, operations and administration (the “Corporate Objectives”). The Board believes the Corporate Objectives will contribute to the long-term success of the Company by aligning with and driving the execution of the Company’s business strategy. For fiscal 2021, the corporate objectives related to awarding incentive bonus payments consisted of:

•

Clinical (Pancreatic): Complete full enrollment of TYME-88-PANC trial.

•

Clinical (Other): Initiate one clinical trial in an indication other than pancreatic cancer or sarcoma.

•

Pre-Clinical: Present updated pre-clinical data regarding SM-88’s mechanism of action at a medical meeting, present pre-clinical data on TYME-18 at a medical meeting, and initiate clinical pharmacology studies required for a New Drug Application submission.

•

Operations: Maintain adequate clinical supply, including for Tyme studies, Precision Promise and HoPES, identify second API manufacturing source, execute on the SM-88 integrated plan for commercial launch, and apply for either Orphan Drug, Fast Track or Breakthrough designation for SM-88.

•

Administration/Financial: Raise additional capital and complete transition from external accountants and begin transition to new accounting platform.

Each year, the Compensation Committee recommends, and the Board approves and establishes, the target cash incentive opportunity for each executive officer assuming full achievement against the Corporate Objectives. For 2021, the target cash incentive opportunity for each of the Named Executive Officer was considered to be within the competitive range of market data provided to the Compensation Committee by Pearl Meyer. The following table shows the amount of the target incentive for each Named Executive Officer as of March 31, 2021 as a percentage of salary and the dollar amount:


Name	Target Incentive 2021			Target Incentive Bonus 2021
Richard Cunningham		50	%	$	97,000	⁽¹⁾
Steve Hoffman		60	%	$	341,550
James Biehl		40	%	$	186,300
Jonathan Eckard		40	%	$	160,000

(1)

Mr. Cunningham joined Tyme on November 23, 2020 and any target incentive award is prorated for the partial year of service.

At the end of the fiscal year, the Compensation Committee reviews and approves the level of the Company’s achievement against the Corporate Objectives, except for the CEO’s achievement, which is approved by the whole Board, excluding the CEO. In ~~May 2018, after consultation with Pearl Meyer,~~addition to its assessment of achievement against each Corporate Objective, the Compensation Committee may consider Tyme’s performance as a whole during the fiscal year, including matters not included in the Corporate Objectives. In reviewing the Company’s level of achievement against the Corporate Objectives, the Compensation Committee determined that the Company executed on each of the goals and approved the recommended incentive bonus funding level at 80%. In making this determination, the committee acknowledged that some of the corporate objectives were impacted by the strategic review undertaken over the last several months of the fiscal year. Further, the committee recognized that although the Company did not achieve all of its Corporate Objectives for Clinical and Preclinical Operations, it exceeded its overall Operations and Financial targets, achieving orphan drug designation and completing a $100 million capital raise during the fiscal year, thereby justifying higher bonus funding levels in those categories. Following the determination of the corporate achievement, the Compensation Committee will consider the performance of each Named Executive Officer in arriving at the individual awards, if any, to be made.

The Compensation Committee’s determination of the Company’s level of achievement against the Corporate Objectives is the basis for establishing the funding available for awards. Notwithstanding these determinations, the Compensation Committee and the Board ~~approved salary increases~~can determine individual awards that are above or below the corporate level of achievement based on their evaluation of that individual’s performance. The Compensation Committee believes this flexibility is an important tool to aid in the retention of key talent, reward significant achievement by individual employees, motivate employees and recognize management decision-making focused on generating long-term value for ~~our Chief Executive Officer and Chief Scientific Affairs Officer~~stockholders over short-term achievement of ~~$100,000 and $20,000, respectively, for~~the Corporate Objectives. In fiscal year ~~2019. All other executive salaries remained at fiscal year 2018 levels.~~

~~Discretionary Cash Bonuses~~

~~Historically, we have not had a formal bonus program for our executive employees. In May 2018, after consultation with Pearl Meyer,~~2021, the Compensation Committee ~~recommended,~~considered the 80% achievement of the Corporate Objectives and each Named Executive Officer’s individual performance in determining each Named Executive Officer’s incentive bonus award. In determining the amount of each Named Executive Officer’s award, the Compensation Committee and the Board ~~approved, discretionaryone-time~~ ~~cash bonuses for our named executive officers after~~also considered a Named Executive Officer’s performance against individual goals and the end of fiscal year 2018. These discretionary bonuses are intended to align executive compensation with Company performance and were based on the Board’s evaluation of fiscal year 2018 performance, including but not limited to the following key accomplishments in clinical and scientific milestones, financing activities, presentations in investor conferences and business development:

~~Announcement of successful data for clinical trials and initiation of new trials;~~

~~Publications of clinical data poster presentations at several conferences and symposia;~~

~~Completion of multiple financings;~~

~~Issuance of new US patents;~~

~~Initiation of a collaboration with the University of California San Francisco for prostate cancer; and~~

~~Implementation of new corporate and financing controls and procedures.~~

~~We intend to put a formal cash bonus program in place for fiscal year 2019 after further consultation with Pearl Meyer~~CEO’s input with respect to ~~appropriate~~the performance of the Company and the other executive officers. As a result, Mr. Hoffman was awarded 72%, Mr. Biehl was awarded 92% and Dr. Eckard was awarded 90% of their respective targeted bonus amounts.

The following table shows the achievement of the targets ~~taking into consideration our benchmark review~~for each Named Executive Officer as of ~~peer company practices. The targets may~~March 31, 2021 as a percentage of the target incentive bonus amount and the dollar amount:


Name	Achievement Incentive Bonus 2021			Incentive Bonus ($)
Richard Cunningham		90	%	$	87,000	⁽¹⁾
Steve Hoffman		72	%	$	245,916
James Biehl		92	%	$	171,396
Jonathan Eckard		90	%	$	144,650

(1)

Mr. Cunningham joined Tyme on November 23, 2020 and his target incentive award payout was prorated for the partial year of service.

In addition, in connection with hiring Mr. Cunningham as CEO in November 2020, he was awarded a $75,000 sign-on bonus. He would be ~~based on both corporate~~required to repay such amount to the Company if his employment is terminated before the first anniversary of his employment date by the Company for cause or by him other than for good reason (as the terms “cause” and ~~individual performance, or combinations of both, for achievements~~“good reason” are defined in ~~clinical pipeline development, financing, business development or other areas. See “Recent Developments” below.~~his employment agreement).

Stock Option Grants

We provide stock option grants to our executives to complement cash salaries and cash incentives, incentivize new hires to achieve our ~~clinical~~corporate and ~~business development~~strategic goals, and align executive compensation with the

long-term interests of our stockholders and stock value. We historically provided stock option grants to our ~~named executive officers~~Named Executive Officers upon their initial hiring, as negotiated in their employment agreements. ~~We have not had a formal annual executive option award program or long-term incentive plan, but intend to put plans in place in fiscal year 2019.~~ The Compensation Committee has the discretion to grant stock option compensation to promote high performance and achievement of our corporate objectives by our executives. In granting these awards, the Compensation Committee may establish any conditions or restrictions it deems appropriate in accordance with the 2015 Equity Incentive Plan. In addition, our CEO, as sole member of our Non-Executive Equity Incentive Committee, established by the Compensation Committee, has limited discretionary authority to grant stock options under the 2015 Equity Incentive Plan to our ~~executives,~~non-executive employees and consultants, subject to certain volume limitations.

In fiscal 2021, Mr. Biehl and Dr. Eckard were awarded stock options; however, in light of his significant share ownership, Mr. Hoffman was not awarded stock options. Mr. Cunningham was awarded stock options pursuant to his employment agreement and appointment as Chief Executive Officer in November 2020.

Benefits Plans

We believe that establishing competitive benefit packages for our employees is an important factor in attracting and retaining highly qualified personnel. We maintain broad-based benefits that are provided to all employees, including medical insurance, dental insurance, vision insurance, basic life and personal accident insurance, long and short-term disability insurance, medical flexible spending accounts, adoption assistance and commuter benefits. The Company obtains certain of these benefits through Insperity. All of our executive officers are eligible to participate in all of our employee benefit plans, in each case on the same basis as other employees. We generally do not offer our ~~named executive officers~~Named Executive Officers any material compensation in the form of perquisites, but any perquisites provided to our ~~named executive officers~~Named Executive Officers and described in the ~~footnote~~footnotes to the Summary Compensation Table are offered to encourage the long-term retention of our executives.

Limits on Hedging and Pledging

As part of our insider trading policy, all employees, including executive officers, and members of our Board are prohibited from engaging in ~~certain types of~~ hedging transactions involving our securities, ~~specifically~~including short sales and purchases or sales of puts, calls or other derivative securities. Our insider trading policy also prohibits certain types of pledges of our securities by all employees, including executive officers, and members of our Board, specifically purchases of our securities on margin, borrowing against our securities held in a margin account or pledging our securities as collateral for a loan, with an exception for transactions with thepre-approval of our Chief ~~Financial~~Compliance Officer.

Tax Considerations

The applicability of Section 162(m) of the Code may affect the tax deductibility of certain portions of ~~named executive officers’~~Named Executive Officers’ compensation. Under Section 162(m) of the Code, the ~~recently enacted~~ Tax Cuts and Jobs Act of 2017 eliminates the performance-based compensation exception such that all compensation over one million dollars paid to “covered employees” would be nondeductible. ~~Where possible,~~Notwithstanding the changes to the tax deductibility requirements of Section 162(m) of the Code, the Company ~~will structure~~continues to believe that a meaningful portion of our executive officers’ compensation ~~for its executive officers in a way that preserves tax deductibility under Section 162(m).~~should be tied to measures of performance of our business.

The Company does not usually consider the tax consequences to ~~named executive officers~~Named Executive Officers of cash compensation or of equity-based compensation, though it considers the tax treatment to the Company fornon-qualified options and thenon-qualifying disposition of qualified options to be favorable.

Consideration of Advisory Vote on Executive Compensation

We ~~did not hold~~held an advisory vote on executive compensation ~~last year~~at the 2020 annual meeting of stockholders (otherwise known as~~“say-on-pay”~~ “Say-on-Pay” votes)~~, as~~ with over 90% of the ~~Company was not required~~votes cast voting to ~~do so. We are holding such~~approve the executive compensation of

the Company’s then-named executive officers. At our 2018 annual meeting of stockholders, the stockholders voted to recommend an advisory vote on the Company’s compensation once every two years and the Company has followed this ~~year.~~recommendation. While~~say-on-pay~~ Say-on-Pay votes are not binding on the Company, the ~~compensation committee~~Compensation Committee and Board will consider the outcome of our~~say-on-pay~~Say-on-Pay votes when making future compensation decisions for our executive officers.

~~Recent Developments~~Use of External Data

As our Company has grown, we have begun evaluating our executive compensation programs with the help of third-party experts to more closely tie executive compensation with corporate performance and align with stockholders’ interests. To this end, we recently engaged Pearl Meyer to assist our Compensation Committee in reviewing our executive compensation policies in comparison to the peer group described below and to advise on the design of our programs moving forward. In connection with this review, we have begun to develop revised executive compensation policies for fiscal year 2019. These changes are being designed to provide an overall compensation strategy and a specific compensation plan that establish competitive base salaries and tie a significant portion of executive compensation to the Company’s success in meeting specified and measurable clinical milestone and business development performance goals. As a result of the information provided from the benchmarking review, we have increased the salaries of the Chief Executive Officer and Chief Scientific Affairs Officer as described above. These changes to our compensation program are expected to include:

~~Establishing a short-term incentive plan with appropriate performance goals for clinical, business development, and financing milestones established annually;~~

~~Implementing a long-term incentive plan covering annual equity awards for executives;~~

~~Reviewing the company’s severance protections for executives; and~~

~~Continuing to benchmark compensation in comparison to our peer group~~

By implementing these contemplated changes, we intend to ensure that part of each executive’s compensation is aligned with stockholder interests and tied to the performance of our stock. We believe that part of overall compensation for senior executives should be “at risk,” i.e., contingent upon successful implementation of the Company’s strategy and achievement of its goals. Individuals with the greatest influence on company-wide performance should have the largest amount of cash benefits and stock-based awards at risk.

~~In conducting its initial benchmarking in May 2018 in~~ consultation with Pearl Meyer, the Company has established the following ~~seventeen~~nineteen companies as its peer ~~group.~~group for fiscal year 2021. We evaluate this group in conjunction with our review of peer compensation data, which is comprised principally of oncology focused non-commercial, biotechnology and pharmaceuticals companies with products generally in Phase II or Phase III clinical trials that Pearl Meyer has deemed to be most comparable to us in market capitalization, ~~and~~ employee head ~~count.~~count and research and development expense.


~~ArQule,~~Actinium Pharmaceuticals, Inc.*		~~Mirati Therapeutics,~~MEI Pharma, Inc.
Calithera Biosciences, Inc.		Mustang Bio, Inc.*
Checkpoint Therapeutics, Inc.		Pieris Pharmaceuticals, Inc.
~~ChemoCentryx,~~Corvus Pharmaceuticals, Inc.		~~Progenics Pharmaceuticals,~~Scholar Rock Holding Corporation *
Enochian Biosciences, Inc.		Sesen Bio, Inc.
Evelo Biosciences, Inc. *		Soligenix, Inc.*
Five Prime Therapeutics, Inc.		~~Stemline Therapeutics,~~Sunesis Pharmaceuticals, Inc.
Geron Corporation		~~Sunesis Pharmaceuticals, Inc.~~
~~Karyopharm Therapeutics Inc.~~		Syndax Pharmaceuticals, Inc.
~~Kura Oncology,~~Infinity Pharmaceuticals, Inc.*		Syros Pharmaceuticals, Inc.
Leap Therapeutics, Inc.		~~ZIOPHARM Oncology, Inc.~~
~~Merrimack Pharmaceuticals, Inc.~~

~~Our~~

*	Indicates a new peer group company since the 2021 fiscal year.

We compare our executive compensation program and amounts of compensation against our peer group. We generally target total cash compensation, comprised of base salary and target annual incentive bonuses, to be competitive with the 50th percentile of the market. For fiscal year 2021, the total cash compensation for our Named Executive Officers generally fell within a competitive range of our target positioning. In addition, we generally grant stock options within a competitive range of the market. We size equity grants based on market data that expresses the awards as a percent of common shares outstanding, although in the future we may change our approach to base the size of equity grants on dollar value. This sizing approach is helpful to ensure that the dilutive effects of the grants are reasonable. In total, we believe that the compensation for our Named Executive Officers was reasonable given our corporate performance and our financial circumstances. As indicated above, our peer group is subject to change over time, and we expect that ~~we and~~ the Compensation Committee and we will continue to periodically review and update the ~~list, including in fiscal year 2019.~~list.

~~COMPENSATION COMMITTEE REPORT~~

~~The Compensation Committee of the Board of Directors of Tyme Technologies, Inc. has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of RegulationS-K~~ with Tyme’s management. Based on such review and discussions, the compensation committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this Proxy Statement.

~~Members of the Compensation Committee~~

~~David Carberry (Chair)~~

~~Paul Sturman~~

~~Tommy G. Thompson~~

EXECUTIVE COMPENSATION

The following table sets forth, with respect to our fiscal years ended March 31, ~~2018~~2021 and ~~2017 and December 31, 2015,~~2020, all compensation earned by or paid to all persons who served as Chief Executive Officer ~~and Chief Financial Officer~~ of our Company at any time during such periods, and ~~up to three of such other~~our two most highly compensated executive officers ~~for such periods whose total annual salary and bonus earned during any such annual period exceeded $100,000~~other than the Chief Executive Officer who were serving as executive officers at the end of the last completed fiscal year (collectively, our “Named Executive Officers”).

Except as noted below, no compensation in the form of stock, options or other equity were granted or issued to any of the persons set forth in the following table during the periods indicated as compensation.

Summary Compensation Table

Name and Principal Position    Year⁽¹⁾
Salary
($)

Bonus
($)

Option
Awards
($)⁽²⁾

All Other
Compensation
($)⁽³⁾

Total
($)

Steve Hoffman, CEO⁽⁴⁾
   2018    $ 450,000    $ 318,500    $ —      $ 11,255    $ 779,755
   2017    $ 450,000    —      $ 3,785,000    $ 11,000    $ 4,246,000
   2015    $ 455,900    —      $ 0    $ 151,000    $ 606,900
Michael Demurjian, COO⁽⁵⁾
   2018    $ 450,000    $ 318,500    $ —      $ 30,545    $ 799,045
   2017    $ 450,000    —      $ 3,785,000    $ 28,500    $ 4,263,500
   2015    $ 457,600    —      $ 0    $ 243,000    $ 700,600
Ben Taylor, CFO, President⁽⁶⁾
   2018    $ 414,875    $ 200,000    $ 54,299    $ 20,115    $ 689,289
   2017    $ —      —      $ 3,839,088    $ —      $ 3,839,088
Jonathan Eckard, Chief Scientific Affairs Officer
   2018    $ 164,861    $ 164,583    $ 1,857,570    $ 13,347    $ 2,200,361
Giuseppe Del Priore, MD, CMO
   2018    $ 400,000    $ 120,000    $ —      $ —      $ 520,000
   2017    $ 400,000    —      $ 3,910,255    $ —      $ 4,310,255


Name and Principal Position	Year		Salary ($)		Bonus ($)		Option Awards ($)⁽¹⁾		Nonequity Incentive Plan Compensation ($)		All Other Compensation ($)⁽²⁾		Total ($)
Richard Cunningham, Chief Executive Officer⁽³⁾		2021		193,750		75,000		1,495,344		87,000		218		1,851,312
Steve Hoffman, former Chief Executive Officer and Chief Science Officer⁽⁴⁾		2021 2020		569,250 550,000		— —		— —		245,916 346,500		4,496 4,289		819,662 900,789
James Biehl, Chief Legal Officer⁽⁵⁾		2021		465,750		—		362,673		171,396		8,379		1,008,198
Dr. Jonathan Eckard, Chief Business Officer⁽⁵⁾		2021		400,000		—		302,227		144,650		11,912		858,789

(1)

On October 27, 2016, the Board approved a change in fiscal year end from December 31 to March 31 of each year. As a result of the change in fiscal year, our Company filed with the SEC a transition report on Form~~10-QT~~ on November 8, 2016. As a result of this change, the data depicted for each year listed in the table above covers the twelve-month periods ended March 31, 2018, March 31, 2017 and December 31, 2015. Salary and total compensation (as calculated in accordance with the table above) for the resulting three-month interim period from January 1, 2016 through March 31, 2016, which is not covered by or depicted in the table above, were as follows: Mr. Hoffman $112,500 and $112,500; Mr. Demurjian $112,500 and $112,500; Mr. Del Priore $100,000 and $100,000.

~~(2)~~

Amounts shown do not reflect compensation actually received by the ~~named executive officer.~~Named Executive Officer. Instead, the amounts reported above in the “Option Awards” column represents the aggregate grant date fair value of option awards granted in the respective fiscal years, as determined in accordance with ASC 718. These values have been determined based on assumptions set forth in Note 1013 to our consolidated financial statements included in our Annual Report on Form10-K for the year-ended March 31, ~~2018.~~2021.

~~(3)~~(2)

All Other Compensation includes health insurance premium payments for ~~2018, 2017~~fiscal year 2021 and ~~2015, and 2015 amounts also includepre-2015~~ ~~advances recognized and expensed in 2015~~2020 as compensation. For ~~2018,~~2021, the Company made health insurance premium payments in the amount of ~~$11,255~~$218 for Mr. Cunningham (Mr. Cunningham has not elected to receive health insurance through the Company and receives only the minimal benefits provided as a matter of course to all employees), $4,496 for Mr. Hoffman, ~~$30,545~~$8,379 for Mr. ~~Demurjian, $20,115~~Biehl and $11,912 for Dr. Eckard. For 2020, the Company made health insurance premium payments in the amount of $4,289 for Mr. ~~Taylor~~Hoffman.

(3)	Mr. Cunningham was appointed as Chief Executive Officer on November 23, 2020 and ~~$13,347 for Dr. Eckard.~~received a sign-on bonus of $75,000.

(4)	Mr. Hoffman also served as ~~President and~~the Company’s Chief Executive Officer ~~of Tyme, Inc. since its incorporation on July 26, 2013 and became our Chief Executive Officer upon~~during the ~~consummation of the Merger on March 5, 2015.~~periods presented until November 23, 2020.

(5)

Because Mr. ~~Demurjian served~~Biehl and Dr. Eckard were not Named Executive Officers for the fiscal year 2021, as ~~Vice President~~permitted by SEC rules and ~~Chief Operating Officer of Tyme, Inc. from its incorporation on July 26, 2013 and became our Chief Operating Officer on March 5, 2015.~~guidance, each executive’s compensation is not disclosed in the table above.

~~(6)~~

Mr. Taylor received 129,957 options in lieu of salary for 2018. Accordingly a portion of the amount reported for Mr. Taylor as “salary” for 2018 in the table above represents the amount foregone in exchange for options. See “Grants of Plan Based Awards During the Fiscal Year Ended March 31, 2018” for more information on this grant.

~~Grants of Plan Based Awards During the Fiscal Year Ended March 31, 2018~~

~~The following table summarizes all option grants during the fiscal year ended March 31, 2018 to the Named Executive Officers.~~

Name
   Grant Date    All Other Option Awards:
Number of Securities
Underlying Options (#) Exercise or
Base Price
Exercise
Price
of Option
Awards

   Grant Date
Fair Value of
Option
Awards⁽⁴⁾
Ben Taylor
   11/22/2017    50,000 ⁽¹⁾   $ 4.10       $ 54,299
Ben Taylor
   11/22/2017    129,957 ⁽²⁾   $ 4.10       $ 141,130
Jonathan Eckard
   8/1/2017    500,000 ⁽³⁾   $ 4.31       $ 1,857,570

~~(1)~~

The option grant vests and is exercisable in two equal installments on the grant date and the one year anniversary of the grant date and has a two year term, subject to earlier termination upon certain events.

~~(2)~~

The option grant vests in six equal installments on the monthly anniversaries of the grant date (21,659.50 each vesting date) and has a two year term, subject to earlier termination upon certain events.

~~(3)~~

The option grant vests 50,000 options on the date of grant, with the remaining options exercisable in four equal installments on the yearly anniversaries of the grant date (112,500 each vesting date) with a ten year term, subject to earlier termination upon certain events.

~~(4)~~

The amounts in the “Grant Date Fair Value of Option Awards” column reflect the aggregate grant date fair value of awards for grants of options to the optionees in fiscal year 2018, computed in accordance with FASB ASC Topic 718. These amounts do not represent the actual amounts paid to or realized by the optionees during fiscal year 2018. These values have been determined based on assumptions set forth in Note 10 to our consolidated financial statements included in our Annual Report on Form~~10-K~~ ~~for the year-ended March 31, 2018.~~

Outstanding Equity Awards as of March 31, ~~2018~~2021

As of March 31, ~~2018,~~2021, the following ~~2015 Plan~~equity awards were outstanding for the benefit of our Named Executive Officers. This table provides information about outstanding unexercised stock options held as of March 31, ~~2018~~2021 by each of the Named Executive Officers ~~which~~that remain outstanding.

   Number of Securities Underlying
Unexercised Options    Option
Exercise
Price ($)    Option
Expiration
Date
Name
   Exercisable (#)    Unexercisable (#)(1)
Steve Hoffman
   305,555    194,445    $ 8.75    05/09/2026
Michael Demurjian
   305,555    194,445    $ 8.75    05/09/2026
Ben Taylor
   375,000    1,125,000    $ 2.95    03/27/2027
   111,638    68,319    $ 4.10    11/22/2019
Jonathan Eckard
   50,000    450,000    $ 4.31    7/31/2027
Giuseppe Del Priore
   25,000    —      $ 3.75    10/21/2026
   25,000    —      $ 2.75    02/08/2027
   229,167    270,833    $ 8.75    05/09/2026


	Option Grant Date			Number of Securities Underlying Unexercised Options				Option Exercise Price ($)		Option Expiration Date
Name	Option Grant Date			Exercisable (#)		Unexercisable (#)		Option Exercise Price ($)		Option Expiration Date
Richard Cunningham		11/25/2020	⁽¹⁾		125,000		1,875,000		1.03		11/24/2030
Steve Hoffman		05/09/2016	⁽²⁾		500,000		—		8.75		05/09/2026
James Biehl		3/28/2017	⁽³⁾		25,000		—		2.95		3/28/2027
		5/24/2018	⁽⁴⁾		75,000		—		2.90		5/24/2028
		9/13/2018	⁽⁵⁾		416,660		83,340		2.42		9/8/2028
		5/3/2019	⁽⁵⁾		147,700		105,500		1.56		5/2/2029
		5/7/2020	⁽¹⁾		67,500		292,500		1.39		5/6/2030
Jonathan Eckard		8/1/2017	⁽⁶⁾		500,000		—		4.31		8/1/2027
		5/24/2018	⁽⁵⁾		275,000		25,000		2.90		5/23/2028
		5/3/2019	⁽⁵⁾		216,237		154,463		1.56		5/2/2029
		5/7/2020	⁽¹⁾		56,250		243,750		1.39		5/6/2030

(1)	The ~~following table shows~~option vests quarterly over 4 years.

(2)	The option vests 1/36th of the total grant every month after the date of grant.

(3)	This option vested 3/4th during quarter ended March 31, 2017 and 1/4th during quarter ended March 31, 2018.

(4)	The option vested during quarter ended June 30, 2018.

(5)	The option vests quarterly over 3 years.

(6)

The option grant, which originally vested 1/10th on the grant date then in four equal annual installments on the anniversary of the grant date, was amended on July 30, 2018 to change the vesting schedule to vest as if the original grant had been made on a three-year vesting schedule with equal quarterly vesting. As of the date ~~of stock options that have not vested as of March 31, 2018 for such Named Executive Officers.~~hereof, the option is fully vested.

Name
   Number of
Stock Options
That Have Not
Vested    Next Vesting
Date from
3/31/2018    Next Vesting
Amount
Remaining Vesting Terms
Steve Hoffman
   194,445    4/9/2018    13,889    1/36th of total grant every
month after date of grant
Michael Demurjian
   194,445    4/9/2018    13,889    1/36th of total grant every
month after date of grant
Ben Taylor
   43,319    4/22/2018    21,660    1/6th of total grant every
month from date of grant
   25,000    11/22/2018    25,000    1/2 of total grant upon two year anniversary of date of grant
   1,125,000    3/27/2019    375,000    1/4th of total grant every anniversary of the date of grant
Jonathan Eckard
   450,000    8/1/2018    112,500    1/4th every anniversary of date of grant
Giuseppe Del Priore
   270,833    4/9/2018    10,417    1/48th of total grant every
month from date of grant

Option Exercises and Stock Vested During the Fiscal Year Ended March 31, ~~2018~~2021

No stock options were exercised by any ~~named executive officer~~Named Executive Officer during the fiscal year ended March 31, ~~2018 and no~~2021. The Company has not made stock ~~awards vested for any named executive officer during fiscal year ended March 31, 2018.~~awards.

Employment Agreements

Richard Cunningham

On ~~March 5, 2015,~~November 24, 2020, the Company entered into an employment ~~agreements~~agreement with its Chief Executive Officer, ~~and Chief Operating Officer.~~Richard Cunningham. Under ~~these agreements, each of such two~~this agreement, the chief executive ~~officers~~officer will be entitled to an annual base salary ~~of $450,000~~ and such ~~performance~~target incentive award bonuses as the Company’s Board may determine, from time to time, in its sole discretion. The base ~~salaries are~~salary is reviewed annually by the Company’s Compensation Committee and Board; provided that the base ~~salaries~~salary may not be decreased from ~~their~~its then current ~~levels~~level due to any Board review. The employment agreement has a term of four years. If employment is terminated by the Company without Cause or by the executive for Good Reason, the executive will be entitled to receive (A)(i) base salary as in effect at the time of such termination to the extent such amount has accrued through the termination date and remains unpaid, (ii) any earned but unpaid incentive award as of the termination date, (iii) any unpaid unreimbursed expenses as of the termination date ((A)(i) through (iii) above, the “Accrued Obligations”) and (B) in return for a timely executed and delivered release, (i) an aggregate amount equal to one year of his base salary, which will be payable in the same amounts and at the same intervals as if the employment period had not ended, (ii) immediate

vesting of the portion of all his time-vesting equity awards under the Company’s 2015 Equity Incentive Plan that would have vested in the 12-month period following the termination date and (iii) if he timely elects continued coverage pursuant to COBRA, payment of his share of the premium cost at the same rate as for active employees of the Company for the 12-month period following the termination date.

If the employment is terminated by the Company without Cause or by the executive for Good Reason, in each case, upon or within 12 months following the consummation of a Change in Control, then the executive will be entitled to (A) the Accrued Obligations; and (B) in return for a timely executed and delivered release, (i) an amount equal to one-and-a-half times one year of base salary, which will be payable in the same amounts and at the same intervals as if the employment period had not ended, (ii) an amount equal to one-and-a-half times his target incentive award for the year in which the termination date occurs (or if it has not yet been established, the target incentive award established for the immediately preceding year), which will be payable in the same manner and at the same time that the Company pays other Company executive incentive awards under the Cash Incentive Plan after the termination date, (iii) immediate vesting of all his time-based equity awards under the 2015 Equity Incentive Plan and (iii) if he timely elects continued coverage pursuant to COBRA, payment of his share of the premium cost at the same rate as for active employees of the Company for the 18-month period following the termination date.

If the employment is terminated for “Cause,” or in the case of the executive’s death or disability, the executive will only be entitled to his base salary through the termination date, plus any accrued and unpaid incentive award as of the termination date. For purposes of these employment agreements, ~~each have~~“Cause” means any one of the following: the executive’s: (i) breach of the employment agreement, (ii) conviction of, guilty plea to, or confession of guilt of, a felony, (iii) materially fraudulent, dishonest or illegal conduct in the performance of services for or on behalf of the Company or any of its affiliates, (iv) any repeated conduct by the executive in material violation of Company written policy (v) any conduct that is materially detrimental to the reputation of the Company or any of its affiliates, (vi) misappropriation of funds of the Company or any of its affiliates, (vii) gross negligence or willful misconduct or willful failure to comply with written directions of the Board which directions are within the scope of executive’s duties, or (viii) engaging in discrimination, sexual or other harassment, retaliation, or any conduct involving an act of moral turpitude. “Good Reason” means a material diminution in the executive’s authority, title, duties or responsibilities, the failure of the Company to make all payments due to the executive under the applicable agreement or otherwise, or the relocation of the executive’s primary office to a location more than 50 miles from the company office.

Steve Hoffman

In connection with Mr. Hoffman stepping down as Chief Executive Officer and continuing as Chief Science Officer, his employment agreement was amended and restated on November 24, 2020. Under this amended and restated agreement, the chief science officer will be entitled to an annual base salary of $500,000 in fiscal year 2022, $450,000 in fiscal year 2023 and thereafter as the Company’s Board may determine, from time to time, in its sole discretion. The base salary is reviewed annually by the Company’s Compensation Committee and Board; provided that the base salary may not be decreased from its then current level due to any Board review provided such salary will never decrease from its then-current level. Mr. Hoffman will also be entitled to a target incentive award of 50% of base salary for fiscal year 2022, 40% of base salary for fiscal year 2023, and thereafter in such amounts as the Company’s Board may determine, from time to time, in its sole discretion, provided such target incentive award shall never be below 40% of Mr. Hoffman’s then-current base salary. The employment agreement has a term of five years; provided, however, that, commencing on the first anniversary of the ~~dates~~date of the ~~agreements~~agreement and on each anniversary thereafter, the term will automatically be extended by one year, such that, at any time during the term of the agreement, the remaining employment term will never be less than four years and one day. If employment is terminated by the Company without Cause or by the executive for Good Reason, the executive will be entitled to receive (i) base salary as in effect at the time of such termination to the extent such amount has accrued through the termination date and remains unpaid, (ii) any earned but unpaid ~~performance bonus~~incentive award as of the termination date, (iii) in return for a timely executed and delivered release, an aggregate amount

equal to the sum of base salary the executive would have received from the date of such termination through the then applicable expiration date, which will be payable in the same amounts and at the same intervals as if the employment period had not ended, and (iv) any unpaid expenses as of the termination date.

~~(vii)~~ (vi) gross negligence or willful misconduct or willful failure to comply with written directions of the Board which directions are within the scope of executive’s duties, ~~under the employment agreement, (viii) engaging in conduct involving an act of moral turpitude,~~ or ~~(ix)~~(vii) a breach of the duty of loyalty to the Company or its ~~Affiliates. For purposes~~Affiliates with respect to its current lines of ~~these employment agreements,~~business. “Good Reason” means the failure of the Company to make all payments due to the executive under the applicable agreement and the continuation thereof for more than five calendar days after notice to the Company of such failure and demand for such outstanding payment(s).

~~In May 2016,~~James Biehl

On September 10, 2018, the Company ~~approved~~entered into an employment agreement with ~~Giuseppe Del Priore, M.D. for~~its Chief Legal Officer, James Biehl. Under this agreement, the ~~position of Chief Medical Officer of the Company with an initial expiration date of October 31, 2016. The agreement could renew for an additionalone-year~~ ~~period unless timely notice of nonrenewal is given or is earlier terminated pursuant~~chief legal officer will be entitled to ~~its terms. The agreement was not renewed and Dr. Del Priore is an “at will” employee. The agreement provided for~~ an annual base salary and such performance bonuses as the Company’s Board may determine, from time to time, in its sole discretion. The base salary is reviewed annually by the Company’s Compensation Committee and Board; provided that the base salary may not be decreased from its then current level due to any Board review. The employment agreement has a term of ~~$400,000~~two and severance benefits equal to three months of salary payable in certain circumstances. The Board also approved the grant to Dr. Del Priore of an option to purchase 500,000 shares of Common Stock vesting over a ~~four- year term on a monthly basis. The exercise price of this option was set at $8.75 per share, which was the closing price for our stock~~half years, provided, however, that, commencing on the ~~OTCBB for the preceding trading day.~~

~~On March 15, 2017, the Company entered into a letter agreement with Ben R. Taylor, which was effective as of March 23, 2017 (the “Effective Date~~”), pursuant to which he became President and Chief Financial Officer of the Company, with service and cash compensation payable effective April 3, 2017, which provides for an annual salary of $450,000 and a term which is scheduled to expire on the~~one-year~~six month anniversary of the ~~Effective Date~~date of the ~~letter~~ agreement ~~unless earlier terminated (the “Taylor Letter Agreement”). The Taylor Letter Agreement (i) could renew for an additionalone-year~~ ~~period unless timely notice of nonrenewal is given or~~and on each subsequent six month anniversary thereafter, the ~~Taylor Letter Agreement is earlier terminated, (ii) provides for severance benefits equal to~~term will automatically be extended by six months, such that, at any time during the term of ~~salary in~~ the ~~event of termination~~agreement, the remaining employment term will never be less than two years and one day. If employment is terminated by the Company without ~~“cause”~~Cause or by the executive for ~~“good reason” (as~~Good Reason, the executive will be entitled to receive (A)(i) base salary as in effect at the time of such ~~terms are defined in~~termination to the ~~Taylor Letter Agreement)~~extent such amount has accrued through the termination date and remains unpaid, (ii) any fully earned and declared but unpaid performance bonus as of the termination date and (iii) any unpaid unreimbursed expenses as of the termination date ((A)(i) through (iii) above, the “Accrued Obligations”) and (B) in return for a timely executed and delivered release, (i) an aggregate amount equal to the sum of his base salary that he would have received from the termination date through the agreement expiration date, which will be payable in the same amounts and at the same intervals as if the employment period had not ended, (ii) immediate vesting of the portion of all his time-vesting equity awards under the Company’s 2015 Equity Incentive Plan (unless the board determines the executive was negligent in the performance of his duties) and (iii) ~~contemplates~~if he timely elects continued coverage pursuant to COBRA, payment of his share of the ~~establishment of a performance bonus opportunity based upon~~premium cost at the ~~achievement of performance criteria and goals approved by the Board. Pursuant to the Taylor Letter Agreement, the Company granted to Mr. Taylor, effective March 27, 2017 (the “Grant Date”), a nonqualified stock option to Mr. Taylor, which enables Mr. Taylor to purchase up to 1,500,000 shares of Common Stock~~same rate as for active employees of the Company ~~at an exercise price per share of $2.95. The Option vests~~for the 12-month period following the termination date.

If the employment is terminated for “Cause,” or in ~~four equal annual installments on each anniversary~~the case of the ~~Grant Date. The Taylor Letter Agreement was amended effective November 29, 2017~~executive’s death or disability, the executive will only be entitled to ~~provide~~the Accrued Obligations. For purposes of these employment agreements, “Cause” means any one of the following: the executive’s: (i) material breach of the employment agreement, (ii) conviction of, guilty plea to, or confession of guilt of, a felony involving the Company, (iii) materially fraudulent, dishonest or illegal conduct in the performance of services for ~~compensation~~or on behalf of ~~Mr. Taylor~~the Company or any of its affiliates, (iv) any repeated conduct by the executive in material violation of Company written policy (v) any conduct that is materially detrimental to the reputation of the Company or any of its affiliates, (vi) misappropriation of funds of the Company or any of its affiliates, (vii) gross negligence or willful misconduct or willful failure to comply with ~~stock options~~written directions of the Board which directions are within the scope of executive’s duties, or (viii) conduct involving an act of moral turpitude. “Good Reason” means a material diminution in ~~lieu~~the executive’s authority, title, duties or responsibilities, the failure of ~~potential future cash compensation..~~the Company to make all

payments due to the executive under the applicable agreement or otherwise, or the relocation of the executive’s primary office to a location more than 25 miles from the company office.

Jonathan Eckard

On ~~August 9, 2017,~~July 31, 2018, the Company entered into ~~a letter~~an amended and restated employment agreement with Jonathan Eckard, ~~pursuant~~now its Chief Business Officer. Under this agreement, the executive will be entitled to ~~which he became Chief Science Affairs Officer of the Company, with~~ an annual base salary ~~of $200,000~~ and ~~a term scheduled~~such performance bonuses as the Company’s Board may determine, from time to ~~expire on theone-year~~ ~~anniversary of the effective date of the letter agreement unless earlier terminated (the “Eckard Letter Agreement”). Following completion of a qualified offering~~time, in its sole discretion. The base salary is reviewed annually by the ~~Company, as such~~Company’s Compensation Committee and Board; provided that the base salary may not be decreased from its then current level due to any Board review. The employment agreement has a one year term that automatically renews unless terminated by either party on 60 days’ notice. If employment is defined in the Eckard Letter Agreement, Mr. Eckard will become entitled to a bonus equal to $155,000 multiplied by the number of years that he has been employed by the Company on the date of the qualified offering, and thereafter, Mr. Eckard’s annual salary would increase to $355,000. The Eckard Letter Agreement (i) could renew for an additional~~one-year~~ ~~term unless timely notice of nonrenewal is given or is earlier~~ terminated ~~(ii) provides for severance, in the event of termination~~ by the Company without ~~cause (as defined in~~Cause or by the ~~Eckard Letter Agreement), equal~~executive for Good Reason, the executive will be entitled to ~~six months’~~receive (A)(i) base salary ~~(as~~as in effect at the time of ~~termination)~~such termination to the extent such amount has accrued through the termination date and ~~immediate vesting~~remains unpaid, (ii) any fully earned and declared but unpaid performance bonus as of ~~112,500 options for Company common stock, all~~the termination date and (iii) any unpaid unreimbursed expenses as of the termination date ((A)(i) through (iii) above, the “Accrued Obligations”) and (B) in return for a timely executed and delivered release, (i) an aggregate amount equal to one year of his base salary, which will be payable in the same amounts and at the same intervals as if the employment period had not ended, (ii) immediate vesting of the portion of all his time-vesting equity awards under the Company’s 2015 Equity Incentive Plan (unless the board determines the executive was negligent in the performance of his duties) and (iii) ~~contemplates the establishment~~if he timely elects continued coverage pursuant to COBRA, payment of a performance bonus opportunity based upon the achievement of performance criteria and goals approved by the Board and conditioned on Mr. Eckard’s continued employment by the Company. Pursuant to the Eckard Letter Agreement, the Board granted to Mr. Eckard options to purchase up to 500,000 shareshis share of the ~~Company’s common stock~~premium cost at a~~per-share~~ ~~exercise price of $4.31 (collectively,~~ the “~~Eckard Options”). 50,000~~same rate as for active employees of the ~~Eckard Options vested upon execution~~Company for the 12-month period following the termination date.

If the employment is terminated for “Cause,” or in the case of the ~~Eckard Employment Agreement. The remaining 450,000 shares subject to~~executive’s death or disability, the ~~Eckard Options are scheduled to vest over a four-year term in equal annual installments beginning on theone-year~~ ~~anniversary of the Eckard~~

~~Options’ grant date, conditioned on Mr. Eckard’s continued employment by the Company on the applicable vesting date.~~

~~Potential Payments Upon Termination or Change of Control~~

We have employment agreements with each of Steve Hoffman, Michael Demurjian, Ben Taylor and Jonathan Eckard that provide for payments to each such Named Executive Officer upon termination of employment under specified circumstances. For information regarding the specific circumstances that would trigger payments and the provision of benefits, the manner in which payments and benefits would be provided and conditions applicable to the receipt of payments and benefits, see “—Employment Agreements” above.

~~The following table sets forth certain pro forma information regarding potential payments and benefits that each Named Executive Officer who was serving as an~~ executive ~~officer on March 31, 2018 would~~will only be entitled to ~~receive upon termination~~the Accrued Obligations. For purposes of these employment agreements, “Cause” means any one of the following: the executive’s: (i) material breach of the employment agreement, (ii) conviction of, guilty plea to, or confession of guilt of, a felony involving the Company, (iii) materially fraudulent, dishonest or illegal conduct in the performance of services for or on behalf of the Company or any of its affiliates, (iv) any repeated conduct by the executive in material violation of Company written policy (v) any conduct that is materially detrimental to the reputation of the Company or any of its affiliates, (vi) misappropriation of funds of the Company or any of its affiliates, (vii) gross negligence or willful misconduct or willful failure to comply with written directions of the Board which directions are within the scope of executive’s duties, or (viii) conduct involving an act of moral turpitude. “Good Reason” means a material diminution in the executive’s authority, title, duties or responsibilities, the failure of the Company to make all payments due to the executive under ~~specified circumstances, assuming that~~ the ~~triggering event occurred on March 31, 2018.~~applicable agreement or otherwise, or the relocation of the executive’s primary office to a location more than 25 miles from the company office.

~~Summary of Potential Payments Upon Termination or Change of Control~~

~~Name and Benefits~~

~~Change of~~
~~Control ($)~~

~~Death or~~
~~Disability ($)~~

~~Termination for Cause~~
~~or Without Good~~
~~Reason ($)~~

~~Termination~~
~~Without Cause or~~
~~With Good~~
~~Reason ($)~~

~~Steve Hoffman~~

~~Cash Severance~~⁽¹⁾

—

~~2,217,338~~

~~Stock Options~~

⁽⁶⁾

—

~~Other Benefits~~

—

~~Total Estimated Value~~

—

~~2,217,338~~

~~Michael Demurjian~~

~~Cash Severance~~⁽²⁾

—

~~2,217,338~~

~~Stock Options~~

⁽⁶⁾

—

~~Other Benefits~~

—

��

—

~~Total Estimated Value~~

—

~~2,217,338~~

~~Ben R. Taylor~~

~~Cash Severance~~⁽³⁾

—

~~225,000~~

~~Stock Options~~

⁽⁶⁾

—

⁽⁴⁾

~~Other Benefits~~

—

~~Total Estimated Value~~

—

~~225,000~~

~~Jonathan Eckard~~

~~Cash Severance~~⁽⁵⁾

—

~~177,500~~

~~Stock Options~~

⁽⁶⁾

—

⁽⁴⁾

~~Other Benefits~~

—

~~Total Estimated Value~~

—

~~177,500~~

~~(1)~~

Mr. Hoffman will receive cash severance representing the remainder of his base salary as of the date of termination through the current expiration date of his employment agreement, March 5, 2020 as well as any fully earned and declared but unpaid performance bonus as of the termination date. For fiscal 2018, discretionary bonuses were determined, approved and paid in May 2018 and formal performance bonus targets or metrics were established at any earlier date. For Mr. Hoffman, such discretionary bonus was $273,500.

~~(2)~~

Mr. Demurjian will receive cash severance representing the remainder of his base salary as of the date of termination through the current expiration date of his employment agreement, March 5, 2020 as well as any

fully earned and declared but unpaid performance bonus as of the termination date. For fiscal 2018, discretionary bonuses were determined, approved and paid in May 2018 and formal performance bonus targets or metrics were established at any earlier date. For Mr. Demurjian, such discretionary bonus was $273,500.

~~(3)~~

Mr. Taylor will receive cash severance representing one half of his base salary as of the date of termination through the current expiration date of his employment agreement, March 21, 2019 as well as any fully earned and declared but unpaid performance bonus as of the termination date. For fiscal 2018, discretionary bonuses were determined, approved and paid in May 2018 and formal performance bonus targets or metrics were established at any earlier date. For Mr. Taylor, such discretionary bonus was $200,000.

~~(4)~~

Upon a termination without Cause, 375,000 and 125,000 options would immediately vest for Messrs. Taylor and Eckard, respectively. All of the options that would vest have exercise prices greater than the closing price of Tyme’s Common Stock as of March 31, 2018.

~~(5)~~

Mr. Eckard will receive cash severance representing one half of his base salary as of the date of termination through the current expiration date of his employment agreement, August 2, 2018 as well as any fully earned and declared but unpaid performance bonus as of the termination date. For fiscal 2018, discretionary bonuses were determined, approved and paid in May 2018 and formal performance bonus targets or metrics were established at any earlier date. For Mr. Eckard, such discretionary bonus was $100,000.

~~(6)~~

~~Under outstanding option award agreements, the Company may accelerate the vesting of options in certain change of control transactions.~~

EQUITY COMPENSATION PLAN INFORMATION

The following table provides certain information with respect to all of our equity compensation plans in effect as of March 31, ~~2018:~~2021:


Plan Category	Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights			Weighted Average Exercise Price		Number of Securities Remaining Available for Issuance Under Equity Compensation Plans⁽³⁾		Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights			Weighted Average Exercise Price		Number of Securities Remaining Available for Issuance Under Equity Compensation Plans (3)
Equity compensation plans approved by stockholders prior to March 31, 2018		5,438,072	⁽¹⁾	$	5.11		7,963,190
Equity compensation plans not approved by stockholders prior to March 31, 2018		59,534	⁽²⁾	$	5.00		—
Equity compensation plans approved by stockholders prior to March 31, 2021									12,588,068	⁽¹⁾	$	2.92		3,374,884
Equity compensation plans not approved by stockholders prior to March 31, 2021									29,767	⁽²⁾	$	5.00		—

Total Equity		5,497,606		$	5.11		7,963,190		12,617,835		$	2.92		3,374,884

(1)

~~Includes 5,438,072~~

12,588,068 shares of our Common Stock are issuable under option awards made prior to March 31, ~~2018~~2021 under our 2015 Equity Incentive Plan and our 2016 Plan, each approved by stockholders; these option awards carry a weighted average exercise price of ~~$5.11~~$2.92 per share. For a description of the terms of the 2015 Equity Incentive Plan and 2016 Plan, please see Note 1013 to the consolidated financial statements presented ~~elsewhere herein.~~in our 2021 Annual Report.

(2)

~~Includes 59,534~~

29,767 shares of our Common Stock are issuable upon the exercise of certain warrants to purchase ~~Common Stock~~common stock as of March 31, ~~2018~~2021 at a weighted average exercise price $5.00 per ~~share;~~share. Each of these warrants may be exercised until December 18, 2025 (the tenth anniversary of the issuance). The warrants described in this ~~sentence~~footnote are limited to warrants issued in return for goods or services provided and do not include warrants issued in connection with capital raising transactions, consistent with applicable SEC disclosure obligations.

(3)	~~Includes 7,963,190~~ 3,374,884 shares of our Common Stock are issuable under awards eligible to be made (and not outstanding) as of March 31, ~~2018~~2021 under our 2015 Equity Incentive Plan and 2016 Plan.

CERTAIN RELATIONSHIPS AND RELATED-PARTY AND OTHER TRANSACTIONS

As a smaller reporting company, SEC rules require us to disclose any transaction ~~since~~for the ~~beginning of the registrant’s~~ last two completed fiscal ~~year~~years or any currently proposed transaction in which our Company is a participant and in which any related person has or will have a direct or indirect material interest involving an amount in excess of ~~$120,000.~~$120,000 or one percent of the average of the Tyme’s total assets at year end for the last two fiscal years. A related person is any executive officer, director, nominee for director or holder of 5% or more of the Company’s ~~common stock~~Common Stock or an immediate family member of any of those persons.

In accordance with such SEC rules, in addition to other disclosures contained elsewhere in this report, we note the following related party transactions that occurred during such period:

The Company was provided legal service by ~~DBR. Mr.~~Faegre Drinker Biddle & Reath LLP (“Faegre Drinker”), which, prior to February 1, 2020, was Drinker Biddle & Reath LLP (“DBR”). James Biehl, ~~a partner of DBR, is a member of~~our Chief Legal Officer, holds the ~~Board and has received, and is entitled to receive, equity compensation payable tonon-employee~~ ~~directors generally under the 2016 Plan, as well as cash compensation payable tonon-employee~~ ~~directors generally. See “DIRECTOR COMPENSATION” and “PROPOSAL NO. 3 APPROVAL OF OUR AMENDED AND RESTATED 2016 STOCK OPTION PLAN FORNON-EMPLOYEE~~ ~~DIRECTORS.”~~consulting role “Senior Counsel” with Faegre Drinker. During the year ending March 31, ~~2018,~~2021, the Company incurred approximately ~~$1,819,000, was~~$0.6 million in legal charges ~~incurred~~ payable to ~~DBR,~~Faegre Drinker, and the Company had approximately ~~$384,000~~$87,000 and ~~$362,000~~$61,000 in accounts payable and accrued expenses payable to ~~DBR~~Faegre Drinker at March 31, ~~2018~~2021 and June 30, ~~2018,~~2021, respectively. During the year ending March 31, 2020, the Company incurred approximately $0.9 million in legal charges payable to Faegre Drinker, and the Company had approximately $73,000 and $235,000 in accounts payable and accrued expenses payable to Faegre Drinker at March 31, 2020 and June 30, 2020, respectively.

As noted above in “Common Stock Ownership,” Michael Demurjian, who beneficially owns more than five percent of the Company’s voting securities, resigned as an executive officer and director of the Company effective March 15, 2019. In connection with his resignation, he entered into a Release Agreement, dated March 15, 2019 (the “Release Agreement”), pursuant to which he is entitled to certain severance payments subject to his compliance with obligations and restrictions under the agreement. Mr. Demurjian is entitled to continued payment of his current base salary through March 5, 2024 pursuant to the terms of his employment agreement with the Company, dated March 5, 2015. Additionally, his vested stock options will remain exercisable until March 5, 2024, and he has forfeited all unvested stock options. Mr. Demurjian has also agreed, among other things, not to compete with the Company and not to solicit the Company’s employees, officers, managers or full-time consultants until March 5, 2024. The Release Agreement also places confidentiality and non-disparagement obligations upon Mr. Demurjian and includes a release of all claims against the Company. The Company likewise has a non-disparagement obligation, ending on March 5, 2024. The Company paid Mr. Demurjian $450,000 of his severance during the 2021 fiscal year and paid $510,000 of his severance during the 2020 fiscal year, which includes a one-time payment of $60,000 to satisfy in full all health benefit obligations under the Release Agreement.

AUDIT COMMITTEE REPORT

With respect to Tyme Technologies, Inc.’s (“Tyme” or the “Company”) financial reporting process, the management of the Company is responsible for establishing and maintaining internal controls and preparing Tyme’s consolidated financial statements. Tyme’s independent registered public accounting firm, Grant Thornton LLP (“GTGrant Thorton”), is responsible for auditing these financial statements. It is the responsibility of the Audit Committee to oversee these activities. The Audit Committee does not itself prepare financial statements or perform audits, and its members are not auditors or certifiers of Tyme’s financial statements. We have relied, without independent verification, on management’s representation that the financial statements have been prepared with integrity and objectivity and in conformity with accounting principles generally accepted in the United States of America and on the representations of GTGrant Thornton included in its audit of Tyme’s consolidated financial statements.

We have reviewed and discussed the audited consolidated financial statements for the fiscal year ended March 31, ~~2018~~2021 with Tyme’s management and with ~~GT,~~Grant Thornton, including the results of the independent registered public accounting firm’s audit of Tyme’s financial statements. We have also discussed with GTGrant Thornton all matters required to be discussed by the Standards of the Public Company Accounting Oversight Board (“PCAOB”) and SEC for communication with audit committees, under which GTGrant Thornton must provide us with additional information regarding the scope and results of its audit of Tyme’s consolidated financial statements.

We have also received and reviewed the written disclosures and the letter from GTGrant Thornton required by applicable requirements of the PCAOB regarding ~~GT’s~~Grant Thornton’s communications with the Audit Committee concerning independence, and have discussed with GTGrant Thornton its independence from Tyme, as well as any relationships that may impact ~~GT’s~~Grant Thornton’s objectivity and independence.

Based on our review of the matters noted above and our discussions with Tyme’s management and independent registered public ~~accountants,~~accountant, we recommended to the Board of Directors that the audited consolidated financial statements be included in Tyme’s Annual Report on Form10-K for the fiscal year ended March 31, ~~2018,~~2021, for filing with the ~~Securities and Exchange Commission.~~SEC.

Members of the Audit Committee

David Carberry (Chair)

Donald DeGolyer

~~Tim~~Timothy C. Tyson

PROPOSAL NO. 2

~~RATIFICATION OF APPOINTMENT OF~~

~~INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM~~

The Audit Committee of our Board has appointed GT as our independent registered public accounting firm for the fiscal year ending March 31, 2019. We are asking our stockholders to ratify the selection of GT as our independent registered public accounting firm. Although ratification is not required by our~~By-Laws~~ or otherwise, we are submitting the election of GT to our stockholders for ratification as a matter of good corporate practice and because we value our stockholders’ views on our independent registered public accounting firm. In the event that our stockholders fail to ratify the selection, the Audit Committee will review its future selection of independent auditors. Even if our stockholders ratify the election, our Audit Committee, in its discretion, may appoint another independent registered public accounting firm at any time during the year if the Audit Committee believes that such a change would be in the best interest of Tyme and our stockholders. Representatives of GT are expected to be present at the Annual Meeting, and they will have the opportunity to make a statement if they so desire and to respond to appropriate questions.

~~The following table presents fees for professional audit services and other services provided to Tyme by GT for the fiscal years ended March 31, 2018 and 2017.~~

   Fiscal 2018 Fiscal 2017
Audit Fees
   $ 480,762 ⁽¹⁾ $ 362,600
Audit-Related Fees
   —   —
Tax Fees
   —   —
All Other Fees
   —   —

~~(1)~~

~~Represents the aggregate fees billed for professional services rendered for the audit and/or reviews of our financial statements.~~

~~Our Audit Committee currently has not established formalpre-approval~~ ~~policies or procedures but all fees described above were approved by the Audit Committee of our Board.~~

The Board of Directors recommends a vote “FOR” the ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2019.

~~PROPOSAL NO. 3~~

APPROVAL OFTO AMEND OUR ~~AMENDED AND RESTATED~~ 2016 STOCK OPTION PLAN FORNON-EMPLOYEE DIRECTORS

We are asking our stockholders to approve an amendment and restatement of the 2016 ~~Stock Option~~ Plan ~~forNon-Employee~~ ~~Directors (the “~~(“Amended and Restated 2016 ~~Plan~~”Plan”). If approved by our stockholders, the amendment and restatement would result in the following material ~~changes~~change to the 2016 Plan:

~~increase~~

Increase the total number of shares of Common Stock authorized and reserved for issuance under the 2016 Plan by ~~2,000,000~~3,000,000 shares to ~~2,750,000 shares; and~~

5,750,000 shares.

~~provide the Compensation Committee discretion to allow different award structures and vesting schedules for grants under the 2016 Plan.~~

On May 24, 2018, the Compensation Committee conducted a review of the Company’s director compensation policy, in consultation with the Company’s independent compensation consultant, Pearl Meyer. In connection with that review, and upon the recommendation of the Compensation Committee,28, 2021, the Board unanimously approved the amendment and restatement of the 2016 Plan, subject to stockholder approval, to ensure that the Board and the Compensation Committee will be able to use the 2016 Plan to make the types of awards, and covering the number of shares, as necessary to meet the Company’s needs. The Board believes that participation in the 2016 Plan by ournon-employee directors promotes the success of the Company’s business by aligning the interests of ournon-employee directors with our stockholders. Further, the proposed changes to the 2016 Plan are intended to better align the Company’s director compensation programs with its peers to make the Company more competitive within its industry and peer group and promote the Company’s goals of attracting and retaining qualified outside directors.

Stockholder approval of the amendment and restatement of the 2016 Plan is necessary under Nasdaq requirements for equity compensation plans. As of July 1, 2021, there remain 889,167 shares available for future awards under the 2016 Plan. If our stockholders do not approve the ~~proposed~~ amendment and restatement of the ~~plan,~~2016 Plan, the ~~plan~~Plan will continue in effect under the terms currently in place and ~~any awards granted tonon-employee~~ ~~directors~~we may have insufficient shares available under the plan to grant our directors equity compensation in future years.

Summary of 2016 Plan Terms, as Amended and Restated ~~2016 Plan will be void.~~

~~Summary~~

~~of 2016 Plan Terms, as Amended and Restated~~

The material features of the Amended and Restated 2016 Plan are described below. The following description of the Amended and Restated 2016 Plan is a summary only and is qualified in its entirety by reference to the complete text of the Amended and Restated 2016 Plan. Stockholders are urged to read the actual text of the Amended and Restated 2016 Plan in its entirety, which is attached to this Proxy Statement as Appendix A.

The purpose of the 2016 Plan is to compensate ournon-employee directors ~~directors~~ for their Board service. Under the 2016 Plan (and under the Amended and Restated 2016 Plan) the Company may issue stock options to thenon-employee directors. ~~directors. Upon the recommendation of the Compensation Committee after its review of the Company’s compensation practices with Pearl Meyer, the Board approved changes to the~~Our current director compensation ~~program, such that the~~ program consists of the following: (i) annual cash retainers of $50,000 for director service, (ii) “Initial Grants” upon a director’s initial appointment to the Board consisting of an immediate stock option grant to acquire of 100,000 shares at a fair ~~market value;~~value exercise price; and (iii) “Annual Grants” for members who continue in service as members of the Board subsequent to each annual meeting of stockholders, occurring subsequent to an Initial Grant, an ~~annual~~annually-fixed stock option grant ~~of 50,000~~(such award was options to purchase 65,000 shares ~~at fair market value.~~in fiscal year 2021). The Initial Grants and Annual Grants have a ten year term, subject to applicable termination or forfeiture provisions, and vest in equal quarterly increments over aone-year period ~~period~~ from the date of grant.

Before the adoption of these changes, such grants consisted of: (i) Initial Grants of 25,000 shares at fair market value; and (ii) Annual Grants 10,000 shares at fair market value. Such stock option awards vested 50% on

~~the date of grant and 50% on the first anniversary of the date of grant. Initial Grants and Annual Grants have a ten year term, subject to applicable termination or forfeiture provisions.~~

Stock options granted under the Amended and Restated 2016 Plan are awarded with an exercise price per share equal to the “Fair Market Value” as determined on the grant date based on the last sale before the grant date, the first sale after the grant date, the closing price on the trading day before or the trading day of the grant date, the arithmetic mean of the high and low prices on the trading day before or the trading day of the grant date or any other reasonable method using actual transactions in such stock as reported on the market.

The Amended and Restated 2016 Plan also enables eachnon-employee director ~~director~~ to elect to receive stock options in lieu of all or part of cash director fees that would otherwise be payable to thatnon-employee director, ~~director,~~ which are otherwise payable at the rate of $12,500 per quarter, or $50,000 per annum, for Board service (the “Cash Election Options”). As such, eachnon-employee director ~~director~~ may elect, in accordance with procedures established by the Board, to receive options with a Black-Scholes-based valuation model value equal to the value

of such cash director fees. Cash Election Options may be elected with atwo- or or five-year term, with the number of options associated with atwo-year term ~~term~~ having a larger number of underlying shares compared to the five-year term options due to the difference in time-value oftwo-year versus ~~versus~~ five-year options under the Black-Scholes based option valuation methodology. Cash Election Options are fully vested on the date of grant. ~~In addition,~~

New Plan Benefits

For the ~~Board approved an amendment of the definition of “Fair Market Value” to be consistent with the definition of such defined term within the 2015 Equity Incentive Plan.~~

~~As of~~year ended March 31, ~~2018,~~2021, the Company has granted awards to sixnon-employee directors ~~directors~~ under the 2016 Director Plan, and ~~seven~~six non-employee directors ~~directors~~ are currently eligible for such awards as of the date of this Proxy Statement. With respect to actual new plan benefits available in the future tonon-employee directors, ~~directors,~~ please note that(1) non-employee directors ~~directors~~ who arere-elected in in connection with the Annual Meeting (and continue service following each annual meeting thereafter) will receive options to purchase ~~50,000~~a number of shares of common stock ~~with~~that is fixed annually after review of benchmarking data, (2) newly appointed directors, if any, would receive a ~~per share exercise price equal~~sign-on grant of options to ~~Fair Market Value~~purchase shares of common stock, which number of options may be changed from the current 100,000 options, and ~~(2) that~~(3) the amount of future Cash Election Options, if any, cannot be determined. Accordingly, it is not possible as of the date of this proxy statement to determine future awards that will be received by our non-employee directors under the Amended and Restated 2016 Plan.

No more than ~~2,750,000~~5,750,000 shares may be issued pursuant to the Amended and Restated 2016 Plan. The Amended and Restated 2016 Plan expires in May 2026.

Federal Income Tax Consequences

Options granted tonon-employee directors (or optionees) are considered nonqualified stock options under the Internal Revenue Code, which we refer to as “NSOs.” An optionee does not recognize taxable income upon the grant of an NSO. Upon the exercise of an NSO, the optionee recognizes ordinary income to the extent the fair market value of the shares received upon exercise of the NSO on the date of exercise exceeds the exercise price. We will receive an income tax deduction in an amount equal to the ordinary income that the optionee recognizes upon the exercise of the stock option. If an optionee sells shares received upon the exercise of an NSO, the optionee recognizes capital gain income to the extent the sales proceeds exceed the fair market value of such shares on the date of exercise.

~~New Plan Benefits~~

~~The following table sets forth all stock options that have been granted to our named executive officers, our current executive officers, ournon-executive~~ ~~officer employees and ournon-employee~~ ~~directors that are subject to stockholder approval of Proposal 3. The closing trading price of our Common Stock on Nasdaq as of July 20, 2018 was $2.91 per share.~~


~~Non-Employee~~ ~~Director~~	~~Number of shares~~ ~~underlying the option~~
~~David Carberry~~		~~75,000~~
~~James Biehl~~		~~75,000~~
~~Donald W. DeGolyer~~		~~100,000~~
~~Gerald H. Sokol~~		~~75,000~~
~~Paul Sturman~~		~~75,000~~
~~Tommy G. Thompson~~		~~75,000~~
~~Timothy C. Tyson~~		~~75,000~~

The Compensation Committee and Board approved the award of the options identified above on May 24, 2018, subject to stockholder approval. The exercise price of these options is $2.90 per share, the closing price of our Common Stock as reported by Nasdaq on the date of grant.

We intend to file with the SEC a Registration Statement on FormS-8 to to register the additional ~~2,000,000~~3,000,000 shares of Common Stock available for issuance under the Amended and Restated 2016 Plan promptly after receiving stockholder approval of the Amended and Restated 2016 Plan.

The Board of Directors recommends a vote “FOR” the approval of ~~our~~the Amended and Restated 2016 ~~Stock Option Plan forNon-Employee~~ ~~Directors.~~Plan.

PROPOSAL NO. 43

~~ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION~~RATIFICATION OF APPOINTMENT OF

~~Pursuant to Section 14A~~INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Audit Committee of our Board has appointed Grant Thornton as our independent registered public accounting firm for the ~~Exchange Act, we~~fiscal year ending March 31, 2022. We are ~~seeking anon-binding~~ ~~advisory vote from~~asking our stockholders to ~~approve~~ratify the ~~compensation~~selection of Grant Thornton as our ~~named executive officers, as set forth in this Proxy Statement. This vote~~independent registered public accounting firm. Although ratification is ~~intended~~not required by our By-Laws or otherwise, we are submitting the election of Grant Thornton to ~~provide an overall assessment of our executive compensation program rather than focus on any specific item of compensation. We are also providing~~ our stockholders ~~with the opportunity to cast an advisory vote on the frequency~~for ratification as a matter of ~~this advisory vote to approve the compensation of our named executive officers in Proposal 5.~~

~~Because the Company was an emerging growth company until March 31, 2018, this is our first stockholder vote to approve the compensation of our named executive officers. The Company welcomes~~good corporate practice and because we value our stockholders’ views on ~~this subject,~~our independent registered public accounting firm. In the event that our stockholders fail to ratify the selection, the Audit Committee will review its future selection of independent auditors. Even if our stockholders ratify the election, our Audit Committee, in its discretion, may appoint another independent registered public accounting firm at any time during the year if the Audit Committee believes that such a change would be in the best interest of Tyme and our ~~Board~~stockholders. Representatives of Grant Thornton are expected to be present at the virtual Annual Meeting, and ~~Compensation~~they will have the opportunity to make a statement if they so desire and to respond to appropriate questions.

The following table presents fees for professional audit services and other services provided to Tyme by Grant Thornton for the fiscal years ended March 31, 2021 and 2020.


	Fiscal 2021		Fiscal 2020
Audit Fees⁽¹⁾	$	368,370	$	407,423
Audit-Related Fees		—		—
Tax Fees		—		—
All Other Fees		—		—

Total	$	368,370	$	407,423

(1)

Represents the aggregate fees billed for professional services rendered for the audit and/or reviews of our financial statements as well as for the review of registration statements filed under the Securities Act of 1933, as amended, including comfort letters and consents for securities offerings and filings made with the SEC.

Our Audit Committee ~~will carefully consider~~currently has not established formal pre-approval policies or procedures but all fees described above were approved by the outcome of this vote consistent with the best interests of all stockholders. As described in detail in the “Compensation Discussion and Analysis”, our philosophy in setting executive compensation is to designed to attract, motivate and retain quality executive officers who will manage and lead the Company and will advance us toward achievementAudit Committee of our ~~clinical and business development goals while being fair and equitable to employees and stockholders. Accordingly, we are seeking a vote on the following resolution:~~Board.

RESOLVED, that the stockholders approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in this Proxy Statement pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the compensation tables and related narrative discussion.

The Board of Directors recommends a~~non-binding~~ vote “FOR” the ~~approval~~ratification of the ~~compensation~~appointment of ~~the Company’s named executive officers~~Grant Thornton LLP as ~~disclosed in this Proxy Statement.~~

~~PROPOSAL NO. 5~~

~~ADVISORY VOTE ON FREQUENCY OF FUTURE~~

~~ADVISORY VOTES ON EXECUTIVE COMPENSATION~~

~~Pursuant to Section 14A of the Exchange Act, we are seeking anon-binding~~ ~~advisory vote from~~ our stockholders to approve the frequency of the advisory vote on the compensation of our named executive officers. Stockholders can indicate their preference on whether we should hold an advisory vote on the compensation of our named executive officers annually, every two years or every three years. Stockholders also have the option to abstain from voting on this matter.

Upon consideration of the Company’s long-term goals, the structure of the Company’s executive compensation program, currently contemplated modifications to such compensation programs and the time necessary to implement and evaluate effective changes in compensation structure, the Board believes that an advisory vote on executive compensation every two years would be most appropriate, as this will allow adequate time between votesindependent registered public accounting firm for the ~~Company to implement its compensation policy changes and engage with stockholders to understand and respond to the results of this advisory vote.~~

While this vote is advisory in nature and therefore will not bind us to adopt any particular frequency, our Board intends to carefully consider the voting results in determining how frequently we will hold future advisory votes on executive compensation.

~~The Board of Directors recommends anon-binding~~ ~~vote to conduct future advisory votes on executive compensation every two years.~~fiscal year ending March 31, 2022.

Householding of Proxy Materials

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for the ~~Proxy Materials~~Notice or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice or single set of ~~Proxy Materials or~~ other Annual Meeting materials addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.

This year, a number of brokers with account holders who are our stockholders will be “householding” our ~~proxy materials.~~Proxy Materials. A single ~~set of Proxy Materials~~Notice will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate Notice or separate set of Proxy Materials, please notify your broker or us. You can make a request by contacting our ~~Finance Department~~Corporate Secretary by phone at (212)461-2315 and selecting option three (investor relations) or by mail at ~~17 State Street – 7th Floor, New York, NY 10004, Attention: Corporate Controller.~~1 Pluckemin Way, Suite 103, Bedminster, NJ 07921. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request “householding” of their communications should contact their brokers.

Availability of Annual Report on Form10-K

We filed our ~~2018~~Annual Report on Form10-K for the fiscal year ended March 31, 2021 with the SEC on June ~~13, 2018.~~10, 2021. We will mail to you without charge, upon written request, a copy of our ~~2018 Form10-K,~~Annual Report, excluding exhibits. Please send the written request to Tyme Technologies, Inc., ~~17 State Street – 7th Floor, New York, NY 10004,~~1 Pluckemin Way, Suite 103, Bedminster, NJ 07921, Attention: ~~Investor Relations.~~Corporate Secretary. Our ~~2018~~Annual Report on Form10-K for the fiscal year ended March 31, 2021 may also be accessed and printed directly from our website at http://www.tymeinc.com under the caption “Investors” or from the SEC’s website at www.sec.gov.

Other Business

Our Board does not know of any other matters to be presented at the Annual Meeting. If any additional matters are properly presented at the Annual Meeting, the persons named in the proxy card will have discretion to vote the shares represented by proxy in accordance with their own judgment on such matters.

It is important that your shares be represented at the Annual Meeting, regardless of the number of shares that you hold. We urge you to vote by ~~executing and returning the~~ proxy ~~card~~ at your earliest convenience or by attending the virtual Annual Meeting.

~~Appendix~~Annex A

TYME TECHNOLOGIES, INC.

2016 STOCK OPTION PLAN FORNON-EMPLOYEE DIRECTORS

As Amended and Restated Effective ~~May 24, 2018~~

, 2021

TABLE OF CONTENTS


		Page
1.	Purpose		A-1
2.	~~A-3~~Definitions		A-1
2.3.	Administration		A-2
~~Definitions~~4.	~~A-3~~Eligibility		A-2
3.5.	~~Administration~~	~~A-4~~
4.	~~Eligibility~~	~~A-4~~
5.	Stock Subject to the Plan		A-2
6.	~~A-5~~Non-Employee Director Options		A-3
6.7.	~~Non-Employee~~ ~~Director Options~~General Provisions	~~A-5~~
7. A-4	~~General Provisions~~	~~A-6~~

Tyme Technologies, Inc.

2016 Stock Option Plan forNon-Employee Directors

As Amended and Restated Effective ~~May 24, 2018~~, 2021

1.	Purpose.

The purpose of the Tyme Technologies, Inc. 2016 Stock Option Plan forNon-Employee Directors (the “Plan”) is to promote the interests of Tyme Technologies, Inc. (the “Company”) and its stockholders by providingNon-Employee Directors with an ownership interest in the Company in order to more closely align their interests with those of the Company’s stockholders and to enhance the Company’s ability to attract and retain highly qualifiedNon-Employee Directors.

2.	Definitions.

The following terms, as used herein, shall have the following meanings:

(a)

“Award” shall mean an Option granted pursuant to the Plan.

(b)

“Award Agreement” shall mean any written agreement, contract or other instrument or document between the Company and a Participant evidencing an Award.

(c)

“Board” shall mean the Board of Directors of the Company.

(d)

“Cause” shall mean (i) the engaging by the Participant in willful misconduct that is materially injurious to the Company, (ii) the embezzlement or misappropriation of funds or property of the Company by the Participant, (iii) the conviction of the Participant of a felony or the entrance of a plea of guilty or nolo contendere by the Participant to a felony, or (iv) the willful failure or refusal by the Participant to substantially perform his duties or responsibilities that continues after being brought to the attention of the Participant (other than any such failure resulting from the Participant’s incapacity due to disability). For purposes of this paragraph, no act, or failure to act, on the Participant’s part shall be considered willful unless done, or omitted to be done, by him not in good faith and without reasonable belief that his action or omission was in the best interest of the Company. Determination of Cause shall be made by the Board in its sole discretion. Any such determination shall be final and binding on a Participant.

(e)

“��Code” shall mean the Internal Revenue Code of 1986, as amended from time to time.

(f)

“Committee” shall mean the Compensation Committee of the Board or, if no such committee has been appointed, a committee of the Board which shall be comprised of at least two members who shall qualify as“non-employee directors” within the meaning of Rule16b-3 issued under the Exchange Act. Prior to the date on which a committee is appointed to administer the Plan, “Committee” shall mean the Board.

(g)

“Common Stock” shall mean the common stock, par value $0.0001 per share, of the Company.

(h)

“Company” shall have the meaning set forth in Section 1 hereof.

(i)

“Effective Date” shall have the meaning set forth in Section 9(j) hereof.

(j)

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time.

(k)

“Fair Market Value” as of a particular date shall mean the fair market value of a share of Common Stock, based on the last sale before the grant date, the first sale after the grant date, the closing price on the trading day before or the trading day of the grant date, the arithmetic mean of the high and low prices on the trading day before or the trading day of the grant date or any other reasonable method using actual transactions in Common Stock as reported on the market. The method of determining Fair

Market Value with respect to an Award shall be determined by the Committee; provided that, if the

Committee does not specify a different method, the Fair Market Value as of a particular date shall be the closing price on the day as of which Fair Market Value is to be determined or, if there is no sale on such date, the next preceding day on which such a sale occurred. Notwithstanding the foregoing, (i) Fair Market Value shall be determined by the Committee in accordance with the applicable provisions ofSection 20.2031-2 of the Federal Estate Tax Regulations, or in any other manner consistent with Code Section 422, and (ii) Fair Market Value shall be determined in accordance with Code Section 409A.

(l)

“Non-Employee Director” shall mean a member of the Board who is not also an employee of the Company or a subsidiary.

(m)

“Option” shall mean the right, granted pursuant to the Plan, to purchase shares of Common Stock.

(n)

“Partial Disability” shall mean that the Committee has determined, in its sole discretion, that a Participant is partially disabled.

(o)

“Participant” shall mean aNon-Employee Director selected by the Committee to receive an Award under the Plan.

(p)

“Permanent Disability” means that the Participant has been determined to be disabled by the Committee in its sole discretion.

(q)

“Plan” shall have the meaning set forth in Section 1 hereof.

(r)

“Plan Year” shall mean the Company’s fiscal year.

(s)

“Retirement” shall mean the Participant’s termination of service on the Board by reason of retirement, as determined by the Committee in its sole discretion.

(t)

“Securities Act” shall mean the Securities Act of 1933, as amended from time to time, and as now or hereafter construed, interpreted and applied by regulations, rulings and cases.

3.	Administration.

(a)

Committee’s Powers. Except as reserved to the discretion of the Board hereunder, the Plan shall be administered by the Committee. The Committee shall have the authority, in its sole discretion, subject to and not inconsistent with the express provisions of the Plan, to administer the Plan. The Committee will have the authority to: (i) construe and interpret the Plan, any Award Agreement and any other agreement or document executed pursuant to the Plan; (ii) prescribe, amend and rescind rules and regulations relating to the Plan or any Award; (iii) select persons to receive Awards; (iv) determine the form and terms of Awards; (v) determine the number of shares of Common Stock subject to Awards; (vi) grant waivers of Plan or Award conditions; (vii) determine the vesting, exercisability and payment of Awards; (viii) correct any defect, supply any omission or reconcile any inconsistency in the Plan, any Award or any Award Agreement; and (ix) make all other determinations necessary or advisable for the administration of the Plan.

(b)

Committee’s Discretion Final. All determinations, decisions and interpretations made by the Committee pursuant to the provisions of the Plan shall be final, conclusive and binding on all parties, includingNon-Employee Directors, the Company, the Company’s stockholders, and any other interested persons.

4.	Eligibility.

EachNon-Employee Director shall be eligible to be selected as a Participant in the Plan. The Committee shall select theNon-Employee Directors to receive Awards and shall determine the number of shares of Common Stock subject to a particular Award in such manner as the Committee determines in its sole discretion.

5.	Stock Subject to the Plan.

(a)

Number of Shares. The maximum number of shares of Common Stock reserved for issuance pursuant to the Plan shall be ~~2,750,000~~5,750,000 subject to equitable adjustment as provided in Section 5(b) below. Such shares may, in whole or in part, be authorized but unissued shares or shares that shall have been or may be reacquired by the Company in the open market, in private transactions or otherwise. If any shares subject to an Award are forfeited, cancelled, exchanged or surrendered or if an Award otherwise terminates or expires without a distribution of shares to the Participant, the shares of Common Stock with respect to such Award shall, to the extent of any such forfeiture, cancellation, exchange, surrender, termination or expiration, again be available for Awards under the Plan.

(b)

Equitable Adjustment. In the event that an extraordinary transaction or other event or circumstance affecting the Common Stock shall occur, including, but not limited to, any extraordinary dividend or other distribution (whether in the form of cash, stock or other property), or recapitalization, stock split, reverse stock split, reorganization, merger, consolidation,spin-off, combination, repurchase, share exchange, sale of assets or other similar transaction or event, and the Committee determines that a change or adjustment in the terms of any Award is appropriate, then the Committee may, in its sole discretion, make such equitable changes or adjustments or take any other actions that it deems necessary or appropriate (which shall be effective at such time as the Committee in its sole discretion determines), including, but not limited to (A) causing changes or adjustments to any or all of (i) the number and kind of shares of stock or other securities or property which may thereafter be issued under the Plan in connection with Awards, (ii) the number and kind of shares of stock or other securities or property issued or issuable in respect of outstanding Awards, and (iii) the exercise price relating to any Award, and (B) canceling outstanding Awards in exchange for replacement awards or cash.

6.	Non-Employee Director Options.

(a)

General. The Committee may grant one or more Options to aNon-Employee Director and will determine (i) the number of shares of Common Stock subject to each such Option, (ii) the exercise price of each such Option, (iii) the period during which each such Option may be exercised, and (iv) all other terms and conditions of each such Option, subject to the terms and conditions of this Section 6.

(b)

Form of Option Award Agreement. Each Option granted pursuant to this Section 6 shall be evidenced by an Award Agreement. Each Award Agreement shall (i) state that the Option constitutes a Nonqualified Stock Option, (ii) state the number of shares of Common Stock to which the Option relates, (iii) contain such other provisions (which need not be the same for eachNon-Employee Director or Option) as the Committee may from time to time approve, and (iv) comply with and be subject to the terms and conditions of the Plan.

(c)

Date of Grant. The date of grant of an Option will be the date on which the Committee makes the determination to grant such Option, unless otherwise specified by the Committee.

(d)

Exercise Period. Each Option shall be exercisable within the times or upon the occurrence of one or more events determined by the Committee and set forth in the Award Agreement governing such Option, provided that no Option will be exercisable after the expiration of ten years from the date the Option is granted. The Committee also may provide for an Option to become exercisable at one time or from time to time, periodically or otherwise, in such number of shares of Common Stock or percentage of share s of Common Stock as the Committee determines. Except as otherwise provided in an Award Agreement and provided that theNon-Employee Director shall have continually served as such from the date of grant through the applicable vesting date, an Option shall become vested on a quarterly basis over a one year period following the date of grant (at a rate of 1/4 per quarter), such that on the first anniversary of the date of grant, the Option will be fully vested. Notwithstanding the foregoing, except as otherwise provided in an Award Agreement, (i) each outstanding Option shall become immediately vested and exercisable in full upon the death of theNon-Employee Director, and (ii) if the

Non-Employee Director’s membership on the Board terminates by reason of Retirement, Permanent

Disability or Partial Disability, any outstanding Option held by suchNon-Employee Director shall become immediately vested and exercisable in full.

(e)

Exercise Price. The exercise price of an Option will be determined by the Committee when the Option is granted and may be not less than 100% of the per share Fair Market Value of the shares of Common Stock subject to such Option on the date of grant of such Option. Payment for the shares of Common Stock purchased shall be made in accordance with Section 6(g) of the Plan.

(f)

Termination. Except as otherwise provided in an Award Agreement, upon the cessation of aNon-Employee Director’s membership on the Board for any reason, ~~vestedOptions~~vestedOptions granted to suchNon-Employee Director shall expire upon the earliest to occur of (i) two (2) years from the date of such cessation of Board membership, (ii) the tenth anniversary of the date of grant of the Option, or (iii) the second anniversary of theNon-Employee Director’s death; provided, the periods set forth in clauses (i) and (iii) may be extended upon Board approval. Any portion of an Option that is not vested on theNon-Employee Director’s cessation of Board membership for any reason (or does not become vested by reason of such cessation of membership under paragraph (f) above) shall be permanently forfeited on the date such membership ceases.

(g)

Method and Time of Payment. The Option exercise price shall be paid in full, at the time of exercise, in cash, in shares of Common Stock having a Fair Market Value equal to such Option exercise price, in a combination of cash and Common Stock or, in the sole discretion of the Committee or as set forth in any Award Agreement, through a cashless exercise procedure.

(h)

Elective Options forNon-Employee Directors.EachNon-Employee Director may from time to time elect, in accordance with procedures established by the Committee, to receive in lieu of all or part of any cash fees for services as a director of the Company that would otherwise be payable to suchNon-Employee Director (“Cash Fees”), an Option to purchase shares of Common Stock, which Option shall have a value (as determined in accordance with the Black-Scholes stock option valuation method) as of the date of grant of such Option equal to the amount of such Cash Fees. Notwithstanding anything to the contrary set forth elsewhere in the Plan, (i) the Option shall remain outstanding for a term of two or five years from the date of grant, as elected by theNon-Employee Director, and (ii) the Option shall be fully vested and exercisable at the time of grant.

7.	General Provisions.

(a)

Compliance with Legal Requirements. The Plan and the granting and exercising of Awards, and the other obligations of the Company under the Plan and any Award Agreement or other agreement shall be subject to all applicable federal and state laws, rules and regulations and to such approvals by any regulatory or governmental authority or agency as may be required.

(b)

Nontransferability. Awards shall not be transferable by a Participant other than by will or the laws of descent and distribution, and shall be exercisable during the lifetime of a Participant only by such Participant or his guardian or legal representative; provided, however Awards may be transferred pursuant to a domestic relations order awarding benefits to an “alternate payee” (within the meaning of Code Section 414(p)(8)) that the Committee determines satisfies the criteria set forth in paragraphs (1), (2), and (3) of Code Section 414(p).

(c)

No Right To Continued Directorship. Nothing in the Plan or in any Award granted or any Award Agreement or other agreement entered into pursuant hereto shall confer upon any Participant the right to continue to serve as a director of the Company or to be entitled to any remuneration or benefits not set forth in the Plan or such Award Agreement or other agreement.

(d)

Withholding Taxes. Where a Participant or other person is entitled to receive shares of Common Stock pursuant to the exercise of an Option or is otherwise entitled to receive shares of Common Stock or

cash pursuant to an Award hereunder, the Company shall have the right to require the Participant or

such other person to pay to the Company the amount of any taxes which the Company may be required to withhold before delivery to such Participant or other person of cash or a certificate or certificates representing such shares.

Unless otherwise prohibited by the Committee or by applicable law, a Participant may satisfy any such withholding tax obligation by any of the following methods, or by a combination of such methods: (a) tendering a cash payment; (b) authorizing the Company to withhold from the shares of Common Stock or cash otherwise payable to such Participant through such Award having an aggregate Fair Market Value, determined as of the date the withholding tax obligation arises, equal to the amount of the total withholding tax obligation, and/or (c) delivering to the Company previously acquired shares of Common Stock (none of which shares may be subject to any claim, lien, security interest, community property right or other right of spouses or present or former family members, pledge, option, voting agreement or other restriction or encumbrance of any nature whatsoever) having an aggregate Fair Market Value, determined as of the date the withholding tax obligation arises, equal to the amount of the total withholding tax obligation.

(e)

Amendment and Termination of the Plan. The Board may at any time and from time to time alter, amend, suspend, or terminate the Plan in whole or in part; provided that, any such amendment, suspension or termination of the Plan shall be subject to the requisite approval of the stockholders of the Company to the extent stockholder approval is necessary to satisfy the applicable requirements of the Exchange Act or Rule16b-3 thereunder, any New York Stock Exchange, Nasdaq or securities exchange listing requirements or any other law or regulation. Except as otherwise provided herein, no amendment shall materially adversely affect the rights of any Participant under any Award previously granted under the Plan without such Participant’s consent. Unless sooner terminated by the Board, the Plan will automatically terminate on the tenth anniversary of the Effective Date. If the Plan is terminated, any unexercised Option shall continue to be exercisable in accordance with its terms and the terms of the Plan in effect immediately prior to such termination.

(f)

Participant Rights. Except as provided specifically herein, a Participant or a transferee of an Award shall have no rights as a stockholder with respect to any shares of Common Stock covered by any Award until the date of exercise of the Option and the issuance of a certificate to him or her for such shares in respect of such exercise.

(g)

Unfunded Status of Awards. The Plan is intended to constitute an unfunded plan for incentive compensation. With respect to any payments not yet made to a Participant pursuant to an Award, nothing contained in the Plan or any Award shall give any such Participant any rights that are greater than those of a general creditor of the Company.

(h)

No Fractional Shares. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan or any Award. The Committee shall determine whether cash, other Awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.

(i)

Governing Law. The Plan and all determinations made and actions taken pursuant hereto shall be governed by the laws of the State of Delaware without giving effect to the conflict of laws principles thereof.

(j)

Effective Date. The “Effective Date” of this Plan is May 9, 2016.

(k)

Beneficiary. A Participant may file with the Committee a written designation of a beneficiary on such form as may be prescribed by the Committee and may, from time to time, amend or revoke such designation. If no designated beneficiary survives the Participant, the executor or administrator of the Participant’s estate shall be deemed to be the grantee’s beneficiary.

LOGO

YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. IMMEDIATE Vote by - Internet 24 Hours - a Q Day, U I CK 7 Days a Week E A SY or by Mail Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you TYME TECHNOLOGIES, INC. marked, signed, dated and returned your proxy card. Votes submitted electronically over the Internet must be received by 11:59 p.m., Eastern Time, on August 23, 2021. INTERNET –www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when you access the above website. Follow the prompts to vote your shares. Vote at the Meeting – If you plan to attend the virtual online annual meeting, you will need your 12 digit control number to vote electronically at the annual meeting. To attend the annual meeting, visit: https://www.cstproxy.com/tymeinc/2021 MAIL – Mark, sign and date your proxy card PLEASE DO NOT RETURN THE PROXY CARD IF YOU and return it in the postage-paid envelope ARE VOTING ELECTRONICALLY . provided. FOLD HERE • DO NOT SEPARATE • INSERT IN ENVELOPE PROVIDED PROXY Please mark your votes X THE BOARD OF DIRECTORS OF TYME TECHNOLOGIES, INC. RECOMMENDS A VOTE “FOR” THE ELECTION OF like this EACH DIRECTOR NOMINEE IN PROPOSAL 1 AND “FOR” PROPOSALS 2 3 AND ~~4 AND FOR A FREQUENCY OF “2 YEARS” FOR PROPOSAL 5.~~3. ALL OF THE PROPOSALS ARE PROPOSALS OF THE COMPANY. ~~Please mark your votes like this~~WITHHOLD Proposal 1. AUTHORITY Proposal 3. Election of Directors ~~(1) Steve Hoffman (2) Michael Demurjian (3) Donald W. DeGolyer WITHHOLD AUTHORITY~~ FOR ALL FOR ALL FOR ALL Ratification of appointment of Grant NOMINEES NOMINEES EXCEPT ~~Proposal 3. Approval of Amended and Restated 2016 Stock Option Plan~~Thornton LLP as independent FOR AGAINST ABSTAIN (1) Donald W. DeGolyer (2) Steve Hoffman registered public accounting firm for ~~Non-Employee Directors.~~the fiscal year March 31, 2022. (Instruction: To withhold authority to vote for any individual nominee, mark “For All Except” and ~~write the~~strike a line through that nominee’s name onin the ~~line below)~~list above.) Proposal 2. Approval of Amended and Restated FOR AGAINST ABSTAIN FOR AGAINST ABSTAIN Proposal 4. Advisory vote to approve executive compensation: Proposal 5. Advisory vote on frequency of future advisory votes to approve executive compensation: 1 Year 2 Years 3 Years ABSTAIN In their discretion, the proxies are authorized to vote on such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. This proxy, when properly signed, dated and returned, will be voted as directed herein by the undersigned stockholder. If no direction is made, this proxy will be voted FOR All Nominees in Proposal 1 and FOR Proposals 2, 3 and 4 and 2 Years2016 Stock Option Plan for ~~Proposal 5. Proposal 2. Ratification of appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year March 31, 2019. FOR AGAINST ABSTAIN~~Non-Employee Directors. CONTROL NUMBER Signature Signature, if held jointly Date ~~2018~~, 2021. Note: Please sign exactly as name appears hereon. When shares are held by joint owners, both should sign. When signing as attorney, executor, administrator, trustee, guardian, or corporate officer, please give title as such.

LOGO

Important Notice Regarding the Internet Availability of Proxy Materials for the Annual Meeting of Stockholders ~~The 2018~~To view the 2021 Proxy Statement and ~~our 2018~~2021 Annual Report to Stockholders ~~are available at: http:~~and attend the Annual Meeting, please go to: https://www.cstproxy.com/tymeinc/~~2018~~2021 FOLD HERE • DO NOT SEPARATE • INSERT IN ENVELOPE PROVIDED PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS TYME TECHNOLOGIES, INC. The undersigned ~~hereby authorizes Steve Hoffman~~appoints Richard Cunningham and ~~Ben R. Taylor,~~James Biehl, and each of them, as proxies, each with ~~full of substitution and~~the power to ~~act alone,~~appoint his substitute, and authorizes each of them to represent and to vote, as ~~proxies to vote~~designated on the reverse hereof, all of the shares of ~~Common Stock~~common stock of Tyme Technologies, Inc. held of record by the undersigned ~~would be entitled to vote if personally present and acting~~at the close of business on July 1, 2021 at the Annual Meeting of Stockholders of Tyme Technologies, Inc. to be held on August 24, 2021 at 11:00 ~~a.m.~~AM (Eastern Time), ~~local time, August 23, 2018 at Wyndham Hamilton Park Hotel and Conference Center, 175 Park Avenue, Florham Park, NJ 07932, and~~or at any ~~adjournments~~adjournment or ~~postponements~~postponement thereof. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE ~~UNDERSIGNED ACKNOWLEDGES RECEIPT~~MANNER DIRECTED HEREIN. IF NO CONTRARY DIRECTION IS MADE, THE PROXY WILL BE VOTED IN FAVOR OF ELECTING THE TWO NOMINEES TO THE BOARD OF DIRECTORS IN PROPOSAL 1, IN FAVOR OF PROPOSAL 2 AND PROPOSAL 3, AND IN ACCORDANCE WITH THE JUDGMENT OF THE ~~NOTICE OF ANNUAL MEETING OF STOCKHOLDERS, THE~~PERSONS NAMED AS PROXY ~~STATEMENT FOR~~HEREIN ON ANY OTHER MATTERS THAT MAY PROPERLY COME BEFORE THE ANNUAL MEETING ~~AND THE ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED MARCH 31, 2018.~~OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF. ALL OTHER PROXIES HERETOFORE GIVEN BY THE UNDERSIGNED TO VOTE SHARES OF COMMON STOCK AT THE ANNUAL MEETING ARE EXPRESSLY REVOKED. (Continued, and to be marked, dated and signed, on the other side)


☐		Preliminary Proxy Statement

☐		Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2))

☒		Definitive Proxy Statement

☐		Definitive Additional Materials

☐		Soliciting Material Pursuant to§240.14a-12



☒	No fee required.

☐	Fee computed on table below per Exchange Act Rules14a-6(i)(1) and0-11

	1)	Title of each class of securities to which transaction applies:
	2)	Aggregate number of securities to which transaction applies:
	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	4)	Proposed maximum aggregate value of transaction:
	5)	Total fee paid:

☐	Fee paid previously with preliminary materials.

☐	Check box if any part of the fee is offset as provided by Exchange Act Rule0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	1)	Amount Previously Paid:
	2)	Form, Schedule or Registration Statement No.:
	3)	Filing Party:
	4)	Date Filed:


QUESTIONS AND ANSWERS			1

Why amdid I ~~receiving these materials?~~			1
~~What is included in these materials?~~receive an “Important Notice Regarding the Availability of Proxy Materials”?			1
What is the purpose of ~~the Annual Meeting?~~			1
~~How does the Board of Directors recommend I vote on these proposals?~~this document?			1
Who is entitled to vote at the Annual Meeting?			1
What does it mean if I receive more than one Notice?			1
How do I gain admission to the virtual Annual Meeting or vote my shares at the virtual Annual Meeting?			1
How do I ask questions at the virtual Annual Meeting?			2
What if during the Annual Meeting I have technical difficulties or trouble accessing the live webcast of the Annual Meeting?			2
What is the ~~difference between holding shares as a stockholder~~purpose of ~~record and as a beneficial owner?~~the Annual Meeting?			2
How ~~can~~does the Board of Directors recommend I vote ~~my shares?~~on these proposals?			23
Can I vote my shares without attending the Annual Meeting?			3
If I submit a proxy, how will it be voted?			23
Can I change my vote or revoke my proxy?			2
~~Can I attend the Annual Meeting?~~			34
What constitutes a quorum at the Annual Meeting?			34
What is the voting requirement to approve each of the proposals?			3
~~What are the implications of having recently ceased being an emerging growth company?~~			4
Who pays for the cost of this proxy solicitation?			45
Where can I find the voting results of the Annual Meeting?			5
How do I submit a stockholder proposal for consideration at next year’s annual meeting of stockholders?			5
How do I recommend a director nominee?			56

PROPOSAL NO. 1 ELECTION OF DIRECTORS			7

Donald W. DeGolyer			7
Steve Hoffman			8
~~Michael Demurjian~~			8
~~Donald W. DeGolyer~~Richard Cunningham			8
Gerald H. Sokol			9
~~Thomas (“Tommy”) G. Thompson~~			98
Timothy C. Tyson			9
~~James Biehl~~David Carberry			10
~~David Carberry~~Douglas A. Michels			10
Paul L. Sturman			1110

EXECUTIVE OFFICERS			1211

~~Ben R. Taylor~~James Biehl			11
Dr. Jonathan Eckard			11
Barbara C. Galaini			11
Frank L. Porfido			11
Dr. John Rothman			12
Dr. ~~Giuseppe Del Priore~~			12
~~Dr. Jonathan Eckard~~Jan Van Tornout			12

CORPORATE GOVERNANCE			1413

Code of Ethics			1413
~~Leadership; Controlled Company;~~ Leadership and Board Structure			13
Director Independence			14
Risk Oversight			1514
Communications with Directors			1514
Director Nominations			14
Board Composition and Diversity			15


Policies and Procedures for Related Person Transactions			1615
Board of Directors Meetings and Committees			1615
Audit Committee			16

Compensation Committee			16
~~Compensation~~Nominating and Corporate Governance Committee			17
Strategic Review Committee			17

DIRECTOR COMPENSATION			1819

Director Compensation Table			1819
Outstanding Equity Awards forNon-EmployeeDirectors as of March 31, ~~2018~~			19

~~OWNERSHIP OF COMMON STOCK~~2021			20

~~SECTION 16(a) BENEFICIAL~~ OWNERSHIP ~~REPORTING COMPLIANCE~~OF COMMON STOCK			2221

~~COMPENSATION DISCUSSION AND ANALYSIS~~Security Ownership of Certain Beneficial Owners and Management			21

DELINQUENT SECTION 16(a) REPORTS			23

EXECUTIVE COMPENSATION OVERVIEW			24

Objectives of our Compensation Program			2324
General			24
The Role of the Board, the Compensation Committee and Management			2324
Compensation Consultant Role in Executive Compensation			25
Elements of Compensation			2425
Limits on Hedging and Pledging			2528
Tax Considerations			2528
Consideration of Advisory Vote on Executive Compensation			2628
~~Recent Developments~~Use of External Data			26

~~COMPENSATION COMMITTEE REPORT~~			2729

EXECUTIVE COMPENSATION			2830

Summary Compensation Table			28
~~Grants of Plan-Based Awards During the Fiscal Year ended March 31, 2018~~			2930
Outstanding Equity Awards as of March 31, ~~2018~~2021			2931
Option Exercises and Stock Vested During the Fiscal Year Ended March 31, ~~2018~~2021			3031
Employment Agreements			30
~~Potential Payments upon Termination or Change of Control~~			3231

EQUITY COMPENSATION PLAN INFORMATION			34

~~CERTAIN RELATIONSHIPS AND RELATED-PARTY AND OTHER TRANSACTIONS~~			35

~~AUDIT COMMITTEE REPORT~~CERTAIN RELATIONSHIPS AND RELATED-PARTY AND OTHER TRANSACTIONS			36

~~PROPOSAL NO. 2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM~~AUDIT COMMITTEE REPORT			37

PROPOSAL NO. 32 APPROVAL OF ~~OUR~~ AMENDED AND RESTATED 2016 STOCK OPTION PLAN FORNON-EMPLOYEE DIRECTORS			38

Summary of 2016 Plan ~~Elements,~~Terms, as Amended ~~And~~and Restated			38
New Plan Benefits			39
Federal Income Tax Consequences			39

~~New Plan Benefits~~PROPOSAL NO. 3 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM			40

~~PROPOSAL NO. 4 ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION~~			41

~~PROPOSAL NO. 5 ADVISORY VOTE ON FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE EXECUTIVE COMPENSATION~~			42

Householding of Proxy Materials			4341

Availability of Annual Report on Form10-K			4341
Other Business			4341

ANNEX A—AMENDED AND RESTATED 2016 STOCK OPTION PLAN FOR NON-EMPLOYEE DIRECTORS			A-1


Name	Fees Paid in Cash ($)		Option Awards(1) ($)		All Other Compensation ($)		Total Compensation ($)
Dr. Gerald Sokol		50,000		—		—		50,000
Timothy C. Tyson⁽²⁾		50,000		—		—		50,000
Paul L. Sturman⁽²⁾		50,000		—		—		50,000
James Biehl⁽²⁾		50,000		—		—		50,000
David Carberry⁽²⁾		50,000		—		—		50,000
Tommy G. Thompson⁽³⁾		12,500		—		62,500		75,000


Name and Principal Position	Year⁽¹⁾		Salary ($)		Bonus ($)		Option Awards ($)⁽²⁾		All Other Compensation ($)⁽³⁾		Total ($)
Steve Hoffman, CEO⁽⁴⁾		2018	$	450,000	$	318,500	$	—	$	11,255	$	779,755
		2017	$	450,000		—	$	3,785,000	$	11,000	$	4,246,000
		2015	$	455,900		—	$	0	$	151,000	$	606,900
Michael Demurjian, COO⁽⁵⁾		2018	$	450,000	$	318,500	$	—	$	30,545	$	799,045
		2017	$	450,000		—	$	3,785,000	$	28,500	$	4,263,500
		2015	$	457,600		—	$	0	$	243,000	$	700,600
Ben Taylor, CFO, President⁽⁶⁾		2018	$	414,875	$	200,000	$	54,299	$	20,115	$	689,289
Ben Taylor, CFO, President⁽⁶⁾		2017	$	—		—	$	3,839,088	$	—	$	3,839,088
Jonathan Eckard, Chief Scientific Affairs Officer		2018	$	164,861	$	164,583	$	1,857,570	$	13,347	$	2,200,361
Giuseppe Del Priore, MD, CMO		2018	$	400,000	$	120,000	$	—	$	—	$	520,000
Giuseppe Del Priore, MD, CMO		2017	$	400,000		—	$	3,910,255	$	—	$	4,310,255


Name	Grant Date		All Other Option Awards: Number of Securities Underlying Options (#)			Exercise or Base Price Exercise Price of Option Awards		Grant Date Fair Value of Option Awards⁽⁴⁾
Ben Taylor		11/22/2017		50,000	⁽¹⁾	$	4.10	$	54,299
Ben Taylor		11/22/2017		129,957	⁽²⁾	$	4.10	$	141,130
Jonathan Eckard		8/1/2017		500,000	⁽³⁾	$	4.31	$	1,857,570


	Fiscal 2018			Fiscal 2017
Audit Fees	$	480,762	⁽¹⁾	$	362,600
Audit-Related Fees		—			—
Tax Fees		—			—
All Other Fees		—			—